[(' Genotyping for Stage 2 was performed at the Translational Genomics Research Institute (Phoenix, AZ) on a customized Illumina array, which was designed to capture 49 top loci (P-value ≤ 1×10_−4 ) identified in Stage 1 and previously reported OA variants from large-scale genome-wide association studies (, ).', {'entities': [(117, 125, 'platform')]}),
 (' The V1 and V2 platforms were variants of the Illumina HumanHap550+ BeadChip, including about 25,000 custom SNPs selected by 23andMe, with a total of about 560,000 SNPs.', {'entities': [(46, 54, 'platform')]}),
 (" The V3 platform was based on the Illumina OmniExpress+ BeadChip, with custom content to improve the overlap with 23andMe's V2 array, with a total of about 950,000 SNPs.", {'entities': [(34, 42, 'platform')]}),
 (' In the FinnDiane Study, genotyping was performed with the Illumina 610Quad assay and the quality control was similar to the other studies, as described previously in detail.', {'entities': [(59, 67, 'platform')]}),
 (' Sequencing was performed on an Illumina HiSeq2000. We required an average 20× target capture above 80% coverage, otherwise additional DNA was requested to ‘top up’ the sample.', {'entities': [(32, 40, 'platform')]}),
 (' In the FinnDiane Study, genotyping was performed with the Illumina 610Quad assay and the quality control was similar to the other studies, as described previously in detail.', {'entities': [(59, 67, 'platform')]}),
 (' Sequencing was performed on an Illumina HiSeq2000. We required an average 20× target capture above 80% coverage, otherwise additional DNA was requested to ‘top up’ the sample.', {'entities': [(32, 40, 'platform')]}),
 ('To more comprehensively evaluate genetic variation in the SCN5A -SCN10A  genomic region, we examined SNP associations using the MetaboChip, a high-density custom Illumina iSelect array that includes SNPs from the 1000 Genomes Project (,).', {'entities': [(162, 170, 'platform')]}),
 (' Genome-wide RNA levels were measured using Illumina HT12 v.', {'entities': [(44, 52, 'platform')]}),
 (' Genome-wide SNPs were genotyped in these subjects using Illumina Hap550 and Hap610 arrays, and multidimensional scaling (MDS) was performed.', {'entities': [(57, 65, 'platform')]}),
 (' Participants were genotyped on the HCHS Custom 15041502 B3 array (Illumina Omni2.5M+custom content).', {'entities': [(67, 75, 'platform')]}),
 ('edu/), using the Illumina Human Omni-2.5 Quad BeadChip.', {'entities': [(17, 25, 'platform')]}),
 (' Briefly, samples were genotyped for 589,945 SNPs on the Illumina Human610-Quadv.', {'entities': [(57, 65, 'platform')]}),
 ('HCHS/SOL participants were genotyped using a Custom Illumina Omni2.5M array (HumanOmni2.', {'entities': [(52, 60, 'platform')]}),
 (' The array contains a total of 2,536,661 SNPs of which 2,427,090 are from a standard Illumina Omni2.5M array (HumanOmni2.', {'entities': [(85, 93, 'platform')]}),
 (' All samples were sequenced using Illumina 76 base-pair paired-end reads.', {'entities': [(34, 42, 'platform')]}),
 (' Participants were genotyped on the HCHS Custom 15041502 array (Illumina Omni2.5M + custom content).', {'entities': [(64, 72, 'platform')]}),
 ('\nAdditional exome chip analysis (Illumina Infinium HumanCoreExome BeadChip)\nwas performed on 150 of these 413 cases at the Broad Institute, Boston.', {'entities': [(33, 41, 'platform')]}),
 ('\nAdditional exome chip analysis (Illumina Infinium HumanCoreExome BeadChip)\nwas performed on 150 of these 413 cases at the Broad Institute, Boston.', {'entities': [(33, 41, 'platform')]}),
 (' Additionally, we\nincluded four cohorts with Illumina HumanExome v1.2 and custom genotyping based\nprimarily on prior top results from a previously published COPD GWAS, using results with P\n< 1×10_−4  using plink\n‘–clump’ on the COPDGene non-Hispanic whites to perform\nlinkage disequilibrium pruning (r_2  < 0.', {'entities': [(45, 53, 'platform')]}),
 ('In Stage 1 of the analysis, we used Metal_,  version 2011-03-25 to perform a fixed-effects meta-analysis\nof genome-wide data from 22 studies and four additional COPD cohorts genotyped\non an Illumina HumanExome v1.2 platform with custom content; this content\nincluded a set of COPD candidate genes and regions identified from prior COPD\nGWAS efforts.', {'entities': [(190, 198, 'platform')]}),
 ('\nGenotyping was carried on the Illumina Human 1M-Duo BeadChip array.', {'entities': [(31, 39, 'platform')]}),
 (' Genotype data were analysed using the Illumina 610\u2009k array (https://www.', {'entities': [(39, 47, 'platform')]}),
 ('_, For the 864 samples of the Estonian cohort, the Illumina Human370CNV BeadChips were used for whole-genome genotyping.', {'entities': [(51, 59, 'platform')]}),
 (' Genome-wide genotyping data for the ALL-study was generated by Illumina Human Omni1-Quad arrays.', {'entities': [(64, 72, 'platform')]}),
 ('0 contains 988,306 autosomal SNPs, and genotypes were called using Illumina Genome Studio software v2011.1, genotyping module v1.', {'entities': [(67, 75, 'platform')]}),
 ('Genotyping of 1,564 individuals from 117 EA families was performed at the Center for Inherited Disease Research (CIDR) using the Illumina 2.5M array (Illlumina, San Diego, CA, USA).', {'entities': [(129, 137, 'platform')]}),
 (' For the 758 subjects in the San Diego cohort with the Illumina 550 array genotyping data, 54 subjects were removed due to high SNP missing rates (more than 5% of their SNPs missing).', {'entities': [(55, 63, 'platform')]}),
 (' For the 313 subjects in the San Diego cohort with the Illumina 650 array genotyping data, 13 subjects were removed due to high SNP missing rates.', {'entities': [(55, 63, 'platform')]}),
 (' For the 1,058 subjects in the US cohort with the Illumina Omni 2.5 array genotyping data, there were 2,376,105 measured SNPs, of which 2,116,447 passed QC.', {'entities': [(50, 58, 'platform')]}),
 (' Samples were genotyped using the Illumina Human1M-Duo BeadChip (1,199,187 SNPs) as described previously ().', {'entities': [(34, 42, 'platform')]}),
 ('BioVU subjects were genotyped in the Vanderbilt Technologies for Advanced Genomics (VANTAGE) Core using the Illumina Omni 1-Quad platform.', {'entities': [(108, 116, 'platform')]}),
 (' Genotyping of 3414 individuals from 598 families was performed at the Center for Inherited Disease Research using the Illumina 2.5M array (Illlumina, San Diego, CA, USA).', {'entities': [(119, 127, 'platform')]}),
 (' Individuals were genotyped at Illumina on the HCHS/SOL custom 15041502 B3 array, and imputed to 1000 Human Genomes Phase I data.', {'entities': [(31, 39, 'platform')]}),
 (' Individuals were genotyped at Illumina on the HCHS/SOL custom 15041502 B3 array, and imputed to 1000 Human Genomes Phase I data.', {'entities': [(31, 39, 'platform')]}),
 ('7× through the UK10K consortium on the Illumina HiSeq platform and aligned to the GRCh37 human reference sequence with Burrows-Wheeler Aligner 31. Single-nucleotide variant (SNV) calls were completed with SAMtools/BCFtools, and VQSR and GATK were used to recall these variants.', {'entities': [(39, 47, 'platform')]}),
 (' Genotyping in CAMP was performed using the Illumina HumanHap550v3 BeadChip, and imputation was performed based on the 1,000 Human Genomes Project as previously described.', {'entities': [(44, 52, 'platform')]}),
 (' Genotyping in the GACRS was performed using the Illumina BeadStation 500G platform, and imputation was performed based on the 1,000 Human Genomes Project, using the same methodology as in CAMP.', {'entities': [(49, 57, 'platform')]}),
 ('Individuals were whole-genome sequenced on the Illumina HiSeq 2500 platform using PCR-free library preparation and 100-bp paired-end sequencing, yielding a minimum of 35× coverage.', {'entities': [(47, 55, 'platform')]}),
 (' All variants not present on the Illumina Omni1M array were masked, and the SNVs on chromosome 20 were subsequently imputed back using four different reference panels (1000 Genomes Project, GoNL, custom panel and merged panel).', {'entities': [(33, 41, 'platform')]}),
 ('0 chips, and subjects in the NCI study were genotyped using the Illumina 660W-Quad chips.', {'entities': [(64, 72, 'platform')]}),
 (' Illumina Omni Express genotyping arrays were run on the 806 Mayo Clinic Biobank participants.', {'entities': [(1, 9, 'platform')]}),
 (' Illumina Omni Express genotyping arrays were run on the 806 Mayo Clinic Biobank participants.', {'entities': [(1, 9, 'platform')]}),
 (' In this multi-racial and multi-ethnic study, blood spot samples were collected on more than 800 ELBW infants and analyzed using the Illumina Omni-1 Quad array.', {'entities': [(133, 141, 'platform')]}),
 (' For our study and other secondary genomic analyses performed utilizing this dataset, DNA was extracted from filter paper blood spots for the earliest age available for each subject, amplified and analyzed using the Illumina Omni-1 Quad array, as described below.', {'entities': [(216, 224, 'platform')]}),
 ('SNPs were genotyped using the Illumina HumanOmniExpress BeadChip for REDUCE and CLUE II populations at the Center for Cancer Genomics at Wake Forest University School of Medicine including 730,525 SNPs across the genome.', {'entities': [(30, 38, 'platform')]}),
 ('  () and all subjects used in replication in the original paper were subsequently genotyped using the Illumina 660W-Quad microarray, which included scanning 725 additional gastric cancer cases and 608 additional controls.', {'entities': [(102, 110, 'platform')]}),
 ('0 (574,519 single-nucleotide polymorphisms [SNPs]), and 6602 SardiNIA volunteers were genotyped with four Illumina arrays (OmniExpress, ImmunoChip, Cardio-MetaboChip, and ExomeChip; 890,542 SNPs in total).', {'entities': [(106, 114, 'platform')]}),
 (' Matched gene expression (measured on the Agilent whole human genome 4x44K expression microarray), CpG methylation (measured on the Illumina Infinium HumanMethylation450), copy number alteration (called using the OncoArray), and germline genotype (called using the OncoArray) were available for all of these samples.', {'entities': [(132, 140, 'platform')]}),
 (' Matched gene expression (measured on the Agilent whole human genome 4x44K expression microarray), CpG methylation (measured on the Illumina Infinium HumanMethylation450), copy number alteration (called using the OncoArray), and germline genotype (called using the OncoArray) were available for all of these samples.', {'entities': [(132, 140, 'platform')]}),
 (' ChIP libraries were quantified using Kapa Biosystems Illumina library quantification kit, then 12 pooled for sequencing, which was carried out using single end reads with 75 cycles on a NextSeq 500 (with version 2 chemistry).', {'entities': [(54, 62, 'platform')]}),
 (' ChIP libraries were quantified using Kapa Biosystems Illumina library quantification kit, then 12 pooled for sequencing, which was carried out using single end reads with 75 cycles on a NextSeq 500 (with version 2 chemistry).', {'entities': [(54, 62, 'platform')]}),
 ('Samples were genotyped with the Illumina 610 or Omniexpress chip.', {'entities': [(32, 40, 'platform')]}),
 (' The FoCus samples were typed on the custom Illumina Immunochip and the Omni Express Exome, with 1,024 and 1,713 samples overall before quality control and a variant coverage of 195,732 to 964,193 variants.', {'entities': [(44, 52, 'platform')]}),
 (' Samples were prepared following the protocol for the Illumina Nextera DNA Library Preparation kit and sequenced on the HiSeq Platform as 2 × 125 bp paired-end reads.', {'entities': [(54, 62, 'platform')]}),
 ('  The BLTS participants were genotyped on Illumina Human610-Quadv1_B or HumanCoreExome-12v1-0_C chips.', {'entities': [(42, 50, 'platform')]}),
 (' The BLTS participants were genotyped on Illumina Human610-Quadv1_B or HumanCoreExome-12v1-0_C chips.', {'entities': [(41, 49, 'platform')]}),
 (' Briefly, low-coverage, paired-end read whole-genome sequencing for 1,889 samples was performed on Illumina HiSeq2000 sequencers.', {'entities': [(99, 107, 'platform')]}),
 (' We included only 114 subjects genotyped by the Illumina HumanOmni2.5 array.', {'entities': [(48, 56, 'platform')]}),
 ('  Genotyping was performed at Life and Brain, Bonn, Germany, with the Illumina HumanExome BeadChip v1.0 (N=247,870 variants) or v1.', {'entities': [(70, 78, 'platform')]}),
 (' Illumina’s GenTrain version 2.0 clustering algorithm in GenomeStudio or zCall was used for genotype calling.', {'entities': [(1, 9, 'platform')]}),
 ('  All four CHARGE cohorts were genotyped for the Illumina HumanExome BeadChip v1.0.', {'entities': [(49, 57, 'platform')]}),
 ('  Genotyping was performed in subsets at four centers: NorthShore, Miami, WashU, and CHOP (“CHOP” and “ADC7” datasets) on the Illumina HumanExome BeadChip v1.0.', {'entities': [(126, 134, 'platform')]}),
 ('0 microarray chip, while subjects in the second wave (172 cases and 74 controls) were genotyped using the Illumina HumanOmniExpress-24 beadchip.', {'entities': [(106, 114, 'platform')]}),
 ('  Genotyping was performed at Life and Brain, Bonn, Germany, with the Illumina HumanExome BeadChip v1.0 (N=247,870 variants) or v1.', {'entities': [(70, 78, 'platform')]}),
 (' Illumina’s GenTrain version 2.0 clustering algorithm in GenomeStudio or zCall was used for genotype calling.', {'entities': [(1, 9, 'platform')]}),
 ('  All four CHARGE cohorts were genotyped for the Illumina HumanExome BeadChip v1.0.', {'entities': [(49, 57, 'platform')]}),
 ('  Genotyping was performed in subsets at four centers: NorthShore, Miami, WashU, and CHOP (“CHOP” and “ADC7” datasets) on the Illumina HumanExome BeadChip v1.0.', {'entities': [(126, 134, 'platform')]}),
 (' Genotyping was performed at Life and Brain, Bonn, Germany, with the Illumina HumanExome BeadChip v1.0 (N=247,870 variants) or v1.', {'entities': [(69, 77, 'platform')]}),
 (' Illumina’s GenTrain version 2.0 clustering algorithm in GenomeStudio or zCall was used for genotype calling.', {'entities': [(1, 9, 'platform')]}),
 (' All four CHARGE cohorts were genotyped for the Illumina HumanExome BeadChip v1.0.', {'entities': [(48, 56, 'platform')]}),
 (' Genotyping was performed in subsets at four centers: NorthShore, Miami, WashU, and CHOP (“CHOP” and “ADC7” datasets) on the Illumina HumanExome BeadChip v1.0.', {'entities': [(125, 133, 'platform')]}),
 ('0 microarray chip, while subjects in the second wave (172 cases and 74 controls) were genotyped using the Illumina HumanOmniExpress-24 beadchip.', {'entities': [(106, 114, 'platform')]}),
 (' SNPs rs710446 and rs780094 were genotyped in ASAP on the Illumina 1M chip, while rs4253417, rs76438938 and rs4253421 were imputed to 1000G.', {'entities': [(58, 66, 'platform')]}),
 (' []Illumina’s Human OMNI1-Quad beadchips (catalog #WG-311-1112) were used.', {'entities': [(3, 11, 'platform')]}),
 (' Samples were fragmented and purified with an isopropanol precipitation, re-suspended in Illumina’s resuspension buffer, denatured and the fragmented strands were hybridized onto 50-mer oligos attached to the beads on the beadchip overnight.', {'entities': [(89, 97, 'platform')]}),
 ('GABC and TSS samples were genotyped by using the Illumina HumanOmni1-Quad_v1-0_B array.', {'entities': [(49, 57, 'platform')]}),
 ('Genotyping was performed at the University of Southern California (USC) Genomics Facility using the Illumina Omni-Express BeadChip containing ∼733\u2009000 single-nucleotide polymorphisms (SNPs).', {'entities': [(100, 108, 'platform')]}),
 ('Genotyping was performed using the Illumina PsychArray BeadChip platform, which includes ~600,000 SNPs; this platform has been optimized to capture the maximum amount of information about common variation.', {'entities': [(35, 43, 'platform')]}),
 (' DNA samples of the Tromsø Study were extracted from venous blood and genotyped with the Illumina HumanCoreExome 12v.', {'entities': [(89, 97, 'platform')]}),
 (' Study participants were genotyped with the Illumina HumanOmniExpressExome-8 v.', {'entities': [(44, 52, 'platform')]}),
 (' DNA samples of the Tromsø Study were extracted from venous blood and genotyped with the Illumina HumanCoreExome 12v.', {'entities': [(89, 97, 'platform')]}),
 (' Study participants were genotyped with the Illumina HumanOmniExpressExome-8 v.', {'entities': [(44, 52, 'platform')]}),
 (' Next Generation RNA sequencing using an Illumina HiSeq 2000 was used to evaluate the transcriptome every 2\xa0days from day 2 to 18\xa0days after osteoblast differentiation.', {'entities': [(41, 49, 'platform')]}),
 (' Illumina HumanHT-12 v3 BeadChip human whole-genome expression arrays were used for expression profiling.', {'entities': [(1, 9, 'platform')]}),
 (' Next Generation RNA sequencing using an Illumina HiSeq 2000 was used to evaluate the transcriptome every 2\xa0days from day 2 to 18\xa0days after osteoblast differentiation.', {'entities': [(41, 49, 'platform')]}),
 (' Illumina HumanHT-12 v3 BeadChip human whole-genome expression arrays were used for expression profiling.', {'entities': [(1, 9, 'platform')]}),
 (' Total RNA was extracted and sequenced on an Illumina HiSeq 2000 machine (see  for more details).', {'entities': [(45, 53, 'platform')]}),
 (' Total RNA was extracted and sequenced on an Illumina HiSeq 2000 machine (see  for more details).', {'entities': [(45, 53, 'platform')]}),
 ('All participants were genotyped using the Illumina PsychChip capturing 571K SNPs.', {'entities': [(42, 50, 'platform')]}),
 ('Two of the selected samples lacked sufficient DNA, and the remaining 1,542 subjects were genotyped with the Illumina Omni 1 array, containing probes for 1,008,624 SNPs.', {'entities': [(108, 116, 'platform')]}),
 (' After removal of overlapping participants, genotype data were also available from eight GWAS (4,480 ER-negative cases and 12,632 controls) and 40 studies previously genotyped using the Illumina iCOGS custom array (7,333 ER-negative cases and 42,468 controls).', {'entities': [(186, 194, 'platform')]}),
 (' Gene expression in the METABRIC study had been measured using the Illumina HT12 microarray platform, and we used probe-level estimates.', {'entities': [(67, 75, 'platform')]}),
 (' In brief, genotyping was conducted on the Illumina OmniExpress BeadChip, SNPs included in the analyses were autosomal with a minor allele frequency (MAF) of 5% or more; had a 90% or more completion rate; and no evidence of deviation from Hardy-Weinberg equilibrium (P  > 10_−7 ).', {'entities': [(43, 51, 'platform')]}),
 ('DNA samples were genotyped on an Illumina Human610-Quad or Human660W-Quad BeadChip ().', {'entities': [(33, 41, 'platform')]}),
 (' Genotyping was performed at the University of Southern California using the Illumina 1M chip.', {'entities': [(77, 85, 'platform')]}),
 (' Genotyping was performed at the University of Southern California using the Illumina 1M chip.', {'entities': [(77, 85, 'platform')]}),
 ('5M array with custom content; and MrOS participants were genotyped using the Illumina Omni 1M array.', {'entities': [(77, 85, 'platform')]}),
 (' Genome-wide genotyping of HRS was conducted using the Illumina HumanOmni2.5-4v1 array and screened using standard quality control methods (Supplementary Material).', {'entities': [(55, 63, 'platform')]}),
 (' 35 ‡Khomani, 21 Hadza, and 35 Sandawe individuals were previously genotyped on the Illumina Beadchip 550K custom v2 chip ().', {'entities': [(84, 92, 'platform')]}),
 (' 105 Nama individuals were genotyped on the Illumina Omni2.5 array as part of the African Genome Diversity Project.', {'entities': [(44, 52, 'platform')]}),
 ('  We first ensured uniform SNP IDs by orienting all variants to dbSNP 138, then merged genotype data for KhoeSan individuals across all genotyping platforms (Illumina 550k, OmniExpress, OmniExpressPlus, and Omni2.5).', {'entities': [(158, 166, 'platform')]}),
 ('  Illumina sequencing reads from 91 KhoeSan DNA samples (of which 82 had pigmentation phenotypes) were captured with: 74 samples on an Agilent SureSelect Human All Exon V2 44Mb array (2 × 101 bp reads, sequenced at BGI on a HiSeq 2000), 8 samples on an Agilent SureSelect Human All Exon 50Mb array (2 × 101 bp reads, sequenced at BGI on a HiSeq 2000), and 8 samples on an Agilent SureSelect Human All Exon V4+UTRs 71Mb array (2 × 126 bp reads, sequenced at the New York Genome Center on a HiSeq 2500).', {'entities': [(2, 10, 'platform')]}),
 (' 35 ‡Khomani, 21 Hadza, and 35 Sandawe individuals were previously genotyped on the Illumina Beadchip 550K custom v2 chip ().', {'entities': [(84, 92, 'platform')]}),
 (' 105 Nama individuals were genotyped on the Illumina Omni2.5 array as part of the African Genome Diversity Project.', {'entities': [(44, 52, 'platform')]}),
 (' We first ensured uniform SNP IDs by orienting all variants to dbSNP 138, then merged genotype data for KhoeSan individuals across all genotyping platforms (Illumina 550k, OmniExpress, OmniExpressPlus, and Omni2.5).', {'entities': [(157, 165, 'platform')]}),
 (' Illumina sequencing reads from 91 KhoeSan DNA samples (of which 82 had pigmentation phenotypes) were captured with: 74 samples on an Agilent SureSelect Human All Exon V2 44Mb array (2 × 101 bp reads, sequenced at BGI on a HiSeq 2000), 8 samples on an Agilent SureSelect Human All Exon 50Mb array (2 × 101 bp reads, sequenced at BGI on a HiSeq 2000), and 8 samples on an Agilent SureSelect Human All Exon V4+UTRs 71Mb array (2 × 126 bp reads, sequenced at the New York Genome Center on a HiSeq 2500).', {'entities': [(1, 9, 'platform')]}),
 (' These individuals were unrelated to those in the WGS cohort and had been genotyped using the Illumina HumanHap300, HumanHap610Q, 1M‐Duo or 1.2M-Duo arrays as described previously (,).', {'entities': [(94, 102, 'platform')]}),
 (' Genome-wide SNP genotyping was conducted on approximately 5000 subjects using Illumina’s Omni1-Quad BeadChip, which interrogates 1,011,219 individual SNPs.', {'entities': [(79, 87, 'platform')]}),
 ('4 million SNPs using a custom Illumina array including the HumanOmni2.5-8v1-1 array content plus approximately 150 000 investigator-chosen SNPs.', {'entities': [(30, 38, 'platform')]}),
 (' From the SNN-TXNDC11  region, only rs1802409 was available in the replication dataset; the other SNPs were not included on the Illumina Human Omni2.5S BeadChip.', {'entities': [(128, 136, 'platform')]}),
 (' FHS and CHS CARe data used in this analyses were genotyped on the Illumina IBC chip including ~49 K SNPs in ~2000 candidate genes (for major complex diseases).', {'entities': [(67, 75, 'platform')]}),
 ('2 (Illumina) before alignment to hg19 with STAR.', {'entities': [(3, 11, 'platform')]}),
 ('2 (Illumina) before alignment to hg19 with STAR.', {'entities': [(3, 11, 'platform')]}),
 ('5Exome BeadChip arrays (Illumina, GenomeStudio, Genotyping Module Version 1.9.', {'entities': [(24, 32, 'platform')]}),
 ('Consenting HCHS/SOL subjects were genotyped at Illumina on the HCHS/SOL custom 15041502 B3 array.', {'entities': [(47, 55, 'platform')]}),
 (' The custom array comprised the Illumina Omni 2.5M array (HumanOmni2.', {'entities': [(32, 40, 'platform')]}),
 (' BioMe participants were genotyped with the Illumina HumanOmniExpressExome-8 v.', {'entities': [(44, 52, 'platform')]}),
 ('DNA was extracted from buffy coat and genotyping was done using three versions of the Illumina Multi-Ethnic Global (MEG) array (MEGA n=4,927, MEGA EX n=5,353, and MEG n=4,784; mappable variants available for each were 1,411,334; 1,710,339; and 1,747,639 respectively).', {'entities': [(86, 94, 'platform')]}),
 (" SNP coordinates were remapped based on the TopGenomicSeq provided from Illumina_A  ; all rsID's correspond to build 142 of dbSNP.", {'entities': [(72, 80, 'platform')]}),
 (' The Illumina Omni-Express 760k chip was used for the genome-wide assay of samples in the discovery stage.', {'entities': [(5, 13, 'platform')]}),
 ('Genotyping in the ROOT consortium was conducted using the Illumina HumanOmni2.5-8v1 array.', {'entities': [(58, 66, 'platform')]}),
 (' A total of 2,379,855 SNP probes were attempted in Illumina HumanOmni2.5-8v1 array.', {'entities': [(51, 59, 'platform')]}),
 (' Genotyping in the AABC consortium was conducted using the IlluminaHuman1M-Duo BeadChip.', {'entities': [(59, 67, 'platform')]}),
 (' We conducted whole genome sequencing on the Illumina platform, with average depth of 30x.', {'entities': [(45, 53, 'platform')]}),
 ('Genotyping of the AMBER cases and controls was performed on the Illumina Human Exome Beadchip v1.1 with additional custom content at the Center for Inherited Disease Research (CIDR).', {'entities': [(64, 72, 'platform')]}),
 ('Genotyping for all samples was performed using the Illumina HumanHap610-Quad BeadChips, which contain 620 901 markers.', {'entities': [(51, 59, 'platform')]}),
 ('As previously described, DNA extracted from buffy coat was genotyped on one of three versions of the Illumina Multi-Ethnic Global (MEG) array (MEGA n=4,927, MEGA EX n=5,353, and MEG n=4,784; mappable variants available for each were 1,411,334; 1,710,339; and 1,747,639 respectively) ().', {'entities': [(101, 109, 'platform')]}),
 (' SNP coordinates were remapped based on the TopGenomicSeq provided from Illumina based on build 142 of dbSNP.', {'entities': [(72, 80, 'platform')]}),
 (' Samples for Yale-Penn 1 (n=5540) were genotyped on the Illumina (San Diego, CA, USA) HumanOmni1-Quad v1.0 microarray at the Center for Inherited Disease Research and the Yale Center for Genome Analysis.', {'entities': [(56, 64, 'platform')]}),
 (' Samples for Yale-Penn 2 (n=3675) were genotyped with the Illumina HumanCore Exome array, which includes a total of ∼0.5M SNPs, including exomic SNPs and tagging SNPs.', {'entities': [(58, 66, 'platform')]}),
 (' Genotyping in Yale-Penn 3 (n=592) was performed with the Illumina Multi-Ethnic Genotyping Array, an array targeting ∼1.7M genome-wide markers and optimized for GWAS in populations of diverse ancestries.', {'entities': [(58, 66, 'platform')]}),
 ('p1) (, ), which were genotyped by the Illumina Human 1M array covering ∼1 M total SNPs.', {'entities': [(38, 46, 'platform')]}),
 ('Consenting HCHS/SOL subjects were genotyped at Illumina on the HCHS/SOL custom 15041502 B3 array.', {'entities': [(47, 55, 'platform')]}),
 (' Genotyping of study samples and quality control replicates was conducted at the Cancer Genomics Research Laboratory of the National Cancer Institute on the Illumina (San Diego, CA) HumanOmni5Exome array.', {'entities': [(157, 165, 'platform')]}),
 (' A custom-modified HumanCoreExome array by Illumina was used to obtain the genotypes followed by imputation with the 1000 Genomes Project reference panel (Phase I).', {'entities': [(43, 51, 'platform')]}),
 (' Genotyping was performed by Illumina Microarray Services with a custom array [>2.5 million SNPs from the HumanOmni2.', {'entities': [(29, 37, 'platform')]}),
 (' For participants in the Australian Study, genotype data were derived from several genotyping projects with Illumina 317K, 370K or 610K chips.', {'entities': [(108, 116, 'platform')]}),
 ('As described previously (), we genotyped DNA samples from the LCLs in the Genotype Shared Resource (GSR) at Mayo Clinic using Illumina HumanHap 550K and 510S BeadArrays, which contained 561,298 and 493,750 SNPs, respectively.', {'entities': [(126, 134, 'platform')]}),
 (' The Illumina Human OmniExpressExome -8- v1.0 array was used for genotyping.', {'entities': [(5, 13, 'platform')]}),
 ('edu/magnet/) on the Illumina HiSeq 4000 platform at the Broad Institute Genomic Services.', {'entities': [(20, 28, 'platform')]}),
 (' Genotyping was performed on the Illumina OmniExpressExome-8v1 array and imputed to the HRC reference panel.', {'entities': [(33, 41, 'platform')]}),
 (' Germline DNA was genotyped at the Center for Inherited Disease Research (CIDR) using the Illumina Human OmniExpressExome-8v1 array, designed to human genotype build 37. The GenTrain Version 1.', {'entities': [(90, 98, 'platform')]}),
 (' Genotyping was carried out on the Illumina Human 1M-Duo BeadChip array.', {'entities': [(35, 43, 'platform')]}),
 (' Genome-wide genotyping was carried out using the Illumina Human610 array, as previously described (), in 901 Europeans and 1,394 Indian Asians from amongst the 2,487 LOLIPOP participants with L-arginine measurements.', {'entities': [(50, 58, 'platform')]}),
 (' In brief, transcriptome-wide gene expression in peripheral blood leucocytes was measured using the Illumina Human HT-12 v4 expression BeadChip according to manufacturer’s protocol in two LOLIPOP cohorts of Indian Asian participants.', {'entities': [(100, 108, 'platform')]}),
 ('The Yale-Penn 1 sample was genotyped using the HumanOmni1-Quad array (Illumina) containing approximately 988\u2009000 single-nucleotide polymorphisms (SNPs).', {'entities': [(70, 78, 'platform')]}),
 (' The Yale-Penn 2 sample was genotyped using the HumanCore Exome array (Illumina) containing approximately 266\u2009000 exomic SNPs and approximately 240\u2009000 tagging SNPs for genome-wide imputation.', {'entities': [(71, 79, 'platform')]}),
 ('Replication analyses were performed in five cohorts: (1) Children’s Hospital of Philadelphia (CHOP); (2) Children’s Health Study (CHS); (3) Costa Rica; (4) Sepracor/LOCCS/LODO/Illumina; and (5) i2b2 Crimson Asthma Project (iCAP).', {'entities': [(176, 184, 'platform')]}),
 (' French controls for replication study (FR) were genotyped directly in the laboratory at the Centre Nationale de Genotypage (Evry, France) using the Illumina Human 610Quad Beadchip array according to the manufacturer’s instructions with genotype call rate of more than 95% as previously described [].', {'entities': [(149, 157, 'platform')]}),
 (' The Dutch GWAS cohorts (RCDII, controls, and CeD) were typed with the Illumina Hap550 BeadChip platform imputed with IMPUTE2 [].', {'entities': [(71, 79, 'platform')]}),
 (' HLA types for French controls were obtained using six tagging SNPs from the imputed Illumina Human 660W-Quad BeadChip array as described previously [], and the HLA SNPs for the Dutch GoNL controls in the replication study (NL2) were extracted from the whole-genome sequencing data.', {'entities': [(85, 93, 'platform')]}),
 (' We derived 1,627 cases with colorectal adenocarcinoma from the ongoing Finnish CRC collection and genotyped normal tissues (colorectal tissue or blood) with Illumina (San Diego, CA) HumanOmni2.5–8 SNP arrays.', {'entities': [(158, 166, 'platform')]}),
 ('_,  Illumina HumanCoreExome SNP array data for additional 91 CRC patients and 14,187 Finnish cancer-free controls were obtained from the National FINRISK Study (https://www.', {'entities': [(4, 12, 'platform')]}),
 ('Genotyping with the exome chip was done for this same COPDGene study cohort on Illumina Human exome array (v1.1 and v1.', {'entities': [(79, 87, 'platform')]}),
 ('001, poor Illumina intensity and clustering metrics, deviation from the MAF observed in the 1KGP, by using the criterion (|p1−p0|−0.01)2((p1+p0)(2−p1−p0))>C(|p1−p0|−0.', {'entities': [(10, 18, 'platform')]}),
 ('001, poor Illumina intensity and clustering metrics, deviation from the MAF observed in the 1KGP, by using the criterion (|p1−p0|−0.01)2((p1+p0)(2−p1−p0))>C(|p1−p0|−0.', {'entities': [(10, 18, 'platform')]}),
 (' Genome-wide single-nucleotide polymorphism (SNP) genotyping was conducted on 4622 subjects using Illumina’s (San Diego, CA) HumanOmniExpress (N  = 280) and Omnil-Quad BeadChip (N  = 4342).', {'entities': [(98, 106, 'platform')]}),
 (' cRNAs (750 ng) were hybridized to Illumina HT-12 v3.0 or v4.', {'entities': [(35, 43, 'platform')]}),
 ('0 arrays (Illumina) and incubated overnight for 16 hours at 55°C.', {'entities': [(10, 18, 'platform')]}),
 (' A total of 15, 877 probes passing the filter criteria of Illumina probe detection P -value of <0.01 in at Least 5 percent of the individuals were used for subsequent analysis.', {'entities': [(58, 66, 'platform')]}),
 ('  Using the statistical package PLINK (), we regressed the quantitative outcome, total AUDIT score (among drinkers only, N  = 1036), on allele count assuming an additive model (zero, one or two copies of risk allele), including sex, chip type (Illumina OmniExpress or Omnil-Quad) and 10 principal components (; ) as covariates.', {'entities': [(244, 252, 'platform')]}),
 (' Genome-wide single-nucleotide polymorphism (SNP) genotyping was conducted on 4622 subjects using Illumina’s (San Diego, CA) HumanOmniExpress (N  = 280) and Omnil-Quad BeadChip (N  = 4342).', {'entities': [(98, 106, 'platform')]}),
 (' cRNAs (750 ng) were hybridized to Illumina HT-12 v3.0 or v4.', {'entities': [(35, 43, 'platform')]}),
 ('0 arrays (Illumina) and incubated overnight for 16 hours at 55°C.', {'entities': [(10, 18, 'platform')]}),
 (' A total of 15, 877 probes passing the filter criteria of Illumina probe detection P -value of <0.01 in at Least 5 percent of the individuals were used for subsequent analysis.', {'entities': [(58, 66, 'platform')]}),
 (' Using the statistical package PLINK (), we regressed the quantitative outcome, total AUDIT score (among drinkers only, N  = 1036), on allele count assuming an additive model (zero, one or two copies of risk allele), including sex, chip type (Illumina OmniExpress or Omnil-Quad) and 10 principal components (; ) as covariates.', {'entities': [(243, 251, 'platform')]}),
 (' Genotyping was performed per manufacturer’s protocols for the Illumina HumanHap300 and HumanHap240S (PLCO1), 550K (WHI1, DALS1), 610K (PLCO1, WHI1, DALS1), HumanCytoSNP (PLCO2, VITAL, WHI2, DACHS1, DALS2) and HumanOmniExpress (HPFS, NHS, PHS, DACHS2) assays.', {'entities': [(63, 71, 'platform')]}),
 ('Twins UK subjects had been genotyped using a combination of Illumina arrays (Human Hap300 and the Human Hap610Q) as previously and repeatedly reported, for example.', {'entities': [(60, 68, 'platform')]}),
 (' Methylation of genomic DNA was quantified using the Illumina HumanMethylation450 array according to the manufacturer’s instructions.', {'entities': [(53, 61, 'platform')]}),
 (' Whole-genome genotyping was carried out using the Illumina 317, 610 or OmniExome microarray, with genomic DNA and according to the manufacturer’s instructions.', {'entities': [(51, 59, 'platform')]}),
 (' Gene expression analysis was performed with the Illumina HumanHT-12 v4 BeadChip according to the manufacturer’s protocol.', {'entities': [(49, 57, 'platform')]}),
 (' DNA methylation profiles were obtained using the Illumina Infinium HumanMethylation450 BeadChip according to the manufacturer’s protocol.', {'entities': [(50, 58, 'platform')]}),
 (' Gene expression analysis was performed with the Illumina HumanHT-12 v4 BeadChip according to the manufacturer’s protocol.', {'entities': [(49, 57, 'platform')]}),
 (' DNA methylation profiles were obtained using the Illumina Infinium HumanMethylation450 BeadChip according to the manufacturer’s protocol.', {'entities': [(50, 58, 'platform')]}),
 (' Extracted DNA from cord blood (n  = 237 samples) was genotyped using the Illumina OmniExpress + exome array, and DNA methylation profiling was performed using the Infinium HumanMethylation450 BeadChip.', {'entities': [(74, 82, 'platform')]}),
 (' Pooled sequencing was performed using the Illumina MiSeq platform (300-bp paired-end runs).', {'entities': [(43, 51, 'platform')]}),
 (' We then used Burrows-Wheeler Aligner to map the directional, paired-end Illumina sequencing reads to the reference genome (hg19 build) and quantified methylation from the frequencies of converted and unconverted cytosine residues observed in reads mapped to each CpG site.', {'entities': [(73, 81, 'platform')]}),
 (' Stored serum samples from UHS participants were selected for DNA extraction and genotyping on the Illumina Omni1-Quad BeadChip (see ).', {'entities': [(99, 107, 'platform')]}),
 (' Controls were genotyped on one of three Illumina BeadChip arrays: Omni1-Quad, 1M–Duo, or Omni2.5.', {'entities': [(41, 49, 'platform')]}),
 ('Consenting HCHS/SOL subjects were genotyped at Illumina on the HCHS/SOL custom 15041502 B3 array.', {'entities': [(47, 55, 'platform')]}),
 (' The custom array comprised the Illumina Omni 2.5M array (HumanOmni2.', {'entities': [(32, 40, 'platform')]}),
 (' BioMe participants were genotyped with the Illumina HumanOmniExpressExome-8 v.', {'entities': [(44, 52, 'platform')]}),
 (' Amplification was performed with the Ambion MessageAmp II-Biotin\xa0Enhanced aRNA Amplification Kit (Life Technologies), and transcript levels were measured with the Illumina HumanHT-12 v.', {'entities': [(164, 172, 'platform')]}),
 (' The VQ, UK1, and Scotland1 GWA cohorts were genotyped using Illumina Hap300, Hap240S, Hap370, or Hap550 arrays.', {'entities': [(61, 69, 'platform')]}),
 (' The CCFR1 samples were genotyped using Illumina Hap1M or Hap1M-Duo arrays.', {'entities': [(40, 48, 'platform')]}),
 (' Array data processing and analysis was performed using Illumina GenomeStudio software (version 2011.1).', {'entities': [(56, 64, 'platform')]}),
 ('adjust function  We analysed expression data generated from: (1) Fibroblast, lymphoblastoid cell lines (LCL) and T-cells derived from the umbilical cords of 75 Geneva GenCord individuals; (2) 166 adipose, 156 LCL and 160 skin samples derived from a subset of healthy female twins of the MuTHER resource using Sentrix Human-6 Expression BeadChips (Illumina, San Diego, USA)_,  (3) AgilentG4502A_07_3 custom gene expression data on 154 CRCs as part of the Cancer Genome Atlas project: http://cancergenome.', {'entities': [(347, 355, 'platform')]}),
 (' Array data processing and analysis was performed using Illumina GenomeStudio software (version 2011.1).', {'entities': [(56, 64, 'platform')]}),
 ('adjust function We analysed expression data generated from: (1) Fibroblast, lymphoblastoid cell lines (LCL) and T-cells derived from the umbilical cords of 75 Geneva GenCord individuals; (2) 166 adipose, 156 LCL and 160 skin samples derived from a subset of healthy female twins of the MuTHER resource using Sentrix Human-6 Expression BeadChips (Illumina, San Diego, USA)_,  (3) AgilentG4502A_07_3 custom gene expression data on 154 CRCs as part of the Cancer Genome Atlas project: http://cancergenome.', {'entities': [(346, 354, 'platform')]}),
 ('org) using the Illumina HiSeq platform, and aligned to the GRCh37 human reference using BWA.', {'entities': [(15, 23, 'platform')]}),
 ('All samples were genotyped using Illumina Human660W-Quad v1 DNA Analysis BeadChips at the Mayo Clinic.', {'entities': [(33, 41, 'platform')]}),
 (' Given the use of a common genotyping platform (Illumina Human660W-Quad v1 DNA Analysis BeadChips) and genotyping lab (Mayo Clinic), many common pitfalls in GWAS meta-analysis were avoided, including strand orientation mismatches, imputation reference sample heterogeneity, variable QC criteria, etc.', {'entities': [(48, 56, 'platform')]}),
 (' Given the use of a common genotyping platform (Illumina Human660W-Quad v1 DNA Analysis BeadChips) and genotyping lab (Mayo Clinic), many common pitfalls in GWAS meta-analysis were avoided, including strand orientation mismatches, imputation reference sample heterogeneity, variable QC criteria, etc.', {'entities': [(48, 56, 'platform')]}),
 (' In the RS, exomes of 1764 individuals from the RS-I population were sequenced using the Nimblegen SeqCap EZ V2 capture kit (Roche NimbleGen, Madison, WI, USA) on an Illumina Hiseq2000 sequencer and the TruSeq Version 3 protocol.', {'entities': [(166, 174, 'platform')]}),
 (' ERF has been genotyped with different genotyping platform: Illumina 318\u2009k, 350\u2009k, 610\u2009k and Affymetrics 200\u2009k.', {'entities': [(60, 68, 'platform')]}),
 (' Genotyping was performed at the Mind Research Network (MRN) Neurogenetics Core Lab using the Illumina HumanOmni-Quad BeadChip interrogating 1,140,419 SNPs.', {'entities': [(94, 102, 'platform')]}),
 (' Genotyping in the HVH study was performed using the Illumina 370CNV BeadChip system.', {'entities': [(53, 61, 'platform')]}),
 (' Briefly, 1004 samples from the PEGASUS cohort (discovery samples) were genotyped using the Illumina Human610-Quad BeadChip.', {'entities': [(92, 100, 'platform')]}),
 (' All CATHGEN samples were genotyped using the Illumina OMNI 1-Quad BeadChip, and subject to the same marker and sample QC criteria as described above.', {'entities': [(46, 54, 'platform')]}),
 (' The bar-coded libraries were sequenced by using Illumina’s HiSeq 2500 platform, producing 75-bp paired-end reads that were aligned to the hg19 human genome build using NovoAlign (http://www.', {'entities': [(49, 57, 'platform')]}),
 ('Genome-wide genotype data were collected by using the Illumina HumanOmni1-Quad for African Americans and HumanOmni2.5-8v1 BeadChips (San Diego, CA, USA) for Yoruba.', {'entities': [(54, 62, 'platform')]}),
 (' Using the Illumina Infinium 2.5M-8 microarray, 1450 PediGFR participants were successfully genotyped at ∼2.', {'entities': [(11, 19, 'platform')]}),
 (' In addition we integrated a set of 1,432 out-of-study controls genotyped on the Illumina HumanOmni2.5-Quad from the SIGMA type 2 diabetes study in Mexicans.', {'entities': [(81, 89, 'platform')]}),
 (' Specifically, we used the program SHAPEIT to pre-phase separately the Illumina HumanOmni1-Quad genotype data and HumanOmni2.5M genotype data for SNPs that passed quality control.', {'entities': [(71, 79, 'platform')]}),
 ('Participants were genotyped for approximately 580,000 SNPs on an Illumina HumanCoreExome array plus 15,890 SNPs of custom content designed to cover candidate genes and loci implicated by previous genome-wide or candidate gene studies or from animal models with craniofacial anomalies.', {'entities': [(65, 73, 'platform')]}),
 (' Samples were genotyped on the Illumina Human610-Quad platform and imputed by the GENEVA\xa0Coordinating Center using the IMPUTE2 software and the 1000 Genomes Project reference panel (June 2011 release).', {'entities': [(31, 39, 'platform')]}),
 (' Expression in this dataset was assessed using Illumina Whole-Genome Expression BeadChips (HumanHT-12).', {'entities': [(47, 55, 'platform')]}),
 ('The case cohort was genotyped in the Laboratory of Neurogenetics, National Institute on Aging, using HumanOmniExpress BeadChips (Illumina), which assay 730 525 single nucleotide polymorphisms (SNPs) across the genome.', {'entities': [(129, 137, 'platform')]}),
 (' All DNA samples were assessed for quality control (QC) and genotyped on the Illumina HumanHap550 or HumanHap610 platform at the Center for Applied Genomics (CAG) at CHOP.', {'entities': [(77, 85, 'platform')]}),
 (' The ∼19,000 were genotyped at different times in batches of 200 to 4,436 individuals on different Illumina genotyping chips variously at deCODE, CIDR, and the Diamantina Institute with genotyping mainly on 317K or 370K chips for the older cohort and 610K chips for the younger cohort and a minority of the older cohort.', {'entities': [(99, 107, 'platform')]}),
 (' The ∼19,000 were genotyped at different times in batches of 200 to 4,436 individuals on different Illumina genotyping chips variously at deCODE, CIDR, and the Diamantina Institute with genotyping mainly on 317K or 370K chips for the older cohort and 610K chips for the younger cohort and a minority of the older cohort.', {'entities': [(99, 107, 'platform')]}),
 (' The SPORE-I samples were genotyped at the Genotyping Shared Resource at the Mayo Clinic (Rochester, MN) using the Illumina 660Quad BeadChip.', {'entities': [(115, 123, 'platform')]}),
 (' We used the Illumina VeraCode custom platform to genotype the top SNPs for technical validation in SPORE-I and for stage 2 analyses in the SPORE-II and the GOELAMS-075 trial (Data Supplement).', {'entities': [(13, 21, 'platform')]}),
 (' The Immunochip is an Illumina Infinium microarray comprising 196,524 SNPs and small indel markers selected based on results from genome-wide association studies of 12 different immune-mediated diseases.', {'entities': [(22, 30, 'platform')]}),
 (' The Immunochip is an Illumina Infinium microarray comprising 196,524 SNPs and small indel markers selected based on results from genome-wide association studies of 12 different immune-mediated diseases.', {'entities': [(22, 30, 'platform')]}),
 (' Participants were genotyped using Illumina Hap370CNV chips and completed 6 walks at their preferred walking speed over a 4.6 m computerized GaitRite walkway.', {'entities': [(35, 43, 'platform')]}),
 (' Briefly, newly-genotyped cases and a small number of controls were genotyped on the Illumina 5M array for inclusion in stage I analyses.', {'entities': [(85, 93, 'platform')]}),
 (' All cell lines were from a first passage, cells were harvested when confluent, washed in phosphate buffered saline and frozen in RNA Later (Ambion, Life Technologies, Grand Island, NY), RNA was extracted using Qiagen’s Rneasy extraction kit and amplified using Ambion’s Illumina TotalPrep 96 RNA amplification kit.', {'entities': [(271, 279, 'platform')]}),
 (' Expression was surveyed using the Illumina HG-12 bead arrays and each individual run with 2 replicates.', {'entities': [(35, 43, 'platform')]}),
 (' Gene expression profiling was performed from whole blood using the Illumina HumanHT-12 v3 BeadChip as described elsewhere.', {'entities': [(68, 76, 'platform')]}),
 ('0 BeadChips (Illumina), with whole genome imputation being performed using IMPUTE2 against the 1KG phase I integrated variant set (March 2012).', {'entities': [(13, 21, 'platform')]}),
 ('Genome-wide SNP genotyping of lung cancer cases from MD Anderson Lung Cancer Epidemiology Study, NCI-MD Lung Cancer Case-Control Study, Northern California Lung Cancer Study, Project CHURCH, PLCO, SCCS, and KCI/WSU () was conducted using the Illumina HumanHap 1M Duo chip at the NCI Cancer Genomics Research Laboratory (CGR) in the Division of Cancer Epidemiology and Genetics (DCEG) at the National Cancer Institute.', {'entities': [(242, 250, 'platform')]}),
 (' In the MECC1 study, germline DNA was extracted from peripheral blood samples and genotyped in two batches using the Illumina HumanOmni 2._–  BeadChip, which measures nearly 2.', {'entities': [(117, 125, 'platform')]}),
 (' The Asian 2 consortium was genotyped using the Illumina 1M-duo Array and consisted of studies from the Multiethnic Cohort (MEC; N =3,094), CFR (N =285), Colorectal cancer study on Oahu, Hawaii (CR2&3; N =134), Fukuoka, Japan (N =1,411), Nagano, Japan (N =207) and the Japan Public Health Center-based prospective study (JPHC; N =1,293) after QC filtering_– .', {'entities': [(48, 56, 'platform')]}),
 (' The V1 and V2 platforms were based on the Illumina HumanHap550+ BeadChip, including about 25 000 custom SNPs selected by 23andMe, with a total of about 560 000 SNPs.', {'entities': [(43, 51, 'platform')]}),
 (' The V3 platform was based on the Illumina OmniExpress+ BeadChip, with custom content to improve the overlap with the V2 array, with a total of about 950 000 SNPs.', {'entities': [(34, 42, 'platform')]}),
 (' Genotyping was performed using the Illumina Human1M-Duo genotyping BeadChip.', {'entities': [(36, 44, 'platform')]}),
 (' Genotyping was performed using the Illumina Human1M-Duo genotyping BeadChip.', {'entities': [(36, 44, 'platform')]}),
 ('All participants were genotyped on the Illumina HumanOmni5Exome-4v1-1+exome SNP array at the Center for Inherited Disease Research (CIDR).', {'entities': [(39, 47, 'platform')]}),
 ('The Infinium Human Methylation 450 array (Illumina, San Diego, CA, USA) was used to quantify genome-wide DNA methylation for 748 samples from the Rotterdam study (RS-III) covering 485\u2009577 CpG sites in the genome.', {'entities': [(42, 50, 'platform')]}),
 (' RNA from the same samples was obtained (PAXgene) and hybridized to Illumina HumanHT-12 arrays.', {'entities': [(68, 76, 'platform')]}),
 (' To allow for maximum efficiency and power we pooled samples genotyped on the same platforms, which resulted in three datasets herein referred to as Affy (NHS), Illumina (NHS, NHS2) and Omni (NHS).', {'entities': [(161, 169, 'platform')]}),
 (' To allow for maximum efficiency and power we pooled samples genotyped on the same platforms, which resulted in three datasets herein referred to as Affy (NHS), Illumina (NHS, NHS2) and Omni (NHS).', {'entities': [(161, 169, 'platform')]}),
 ('Blood leukocyte DNA samples were genotyped using the Illumina Human1M-Duo BeadChip (1,199,187 SNPs).', {'entities': [(53, 61, 'platform')]}),
 (' In each study, genotyping was performed using the Illumina HumanHap 300 BeadChips, HumanHap550 or 610 Quad arrays.', {'entities': [(51, 59, 'platform')]}),
 ('Controls genotyped on Illumina Omni1-Quad platform were obtained from the dbGaP, with permission.', {'entities': [(22, 30, 'platform')]}),
 ("Genotyping of the LSL cohort (cases) was performed on an Illumina iScan using the HumanOmniExpress-12 v1.0 BeadChip per the manufacturer's instructions.", {'entities': [(57, 65, 'platform')]}),
 (' Samples were also removed if there were Mendelian errors in >1% of SNPs for a given trio (including misattributed paternity), genotype call rates <98%, and large copy number variations (>1 Mb) based on the Illumina Genome Studio plugin CNVpartition (N  = 20).', {'entities': [(207, 215, 'platform')]}),
 (' These samples also underwent exome-wide genotyping using the Illumina Human Exome BeadChip, which assays for 247,870 SNP markers enriched in the coding exome, following the manufacturer’s specifications.', {'entities': [(62, 70, 'platform')]}),
 (' Cohort 1 involved patients genotyped as part of a GWAS with musculoskeletal adverse events as the phenotype utilizing the Illumina Human610 Quad Beadchip ().', {'entities': [(123, 131, 'platform')]}),
 ('Genotype data for a total of 28 SNPs within CFB  (~6\u2009kb) and 22 SNPs within SLC44A4  (~16\u2009kb) were retrieved from the total genotype data generated on an Illumina Infinium ImmunoChip platform, a custom-made chip with 196\u2009524 markers used in a recently completed trans-ethnic ImmunoChip study.', {'entities': [(154, 162, 'platform')]}),
 (' We also downloaded DNA methylation data which were measured by the Illumina HumanMethylation450 BeadChip from TCGA level 3 data.', {'entities': [(68, 76, 'platform')]}),
 (' Gene expression profiling was generated on the Illumina HT12 arrays and downloaded from the Synapse (syn1757063, see URLs).', {'entities': [(48, 56, 'platform')]}),
 ('0 (Swedish sample 1) and Illumina OmniExpress (Swedish sample 2) chips.', {'entities': [(25, 33, 'platform')]}),
 (' Study-5 (416\u2009BP cases and 2,741 controls) was used as the reference sample here because subjects from Study-5 were genotyped by the high density SNP array (Illumina HumanOmni2.5M).', {'entities': [(157, 165, 'platform')]}),
 (' After preprocessing, the expression levels were analyzed with an Illumina HumanHT-12 v.', {'entities': [(66, 74, 'platform')]}),
 (' Gene expression data from peripheral blood leukocytes were analyzed for 518 individuals from FINRISK2007 with Illumina HumanHT-12 v.', {'entities': [(111, 119, 'platform')]}),
 (' Adaptor ligated DNA fragments of proper size were enriched with PCR reaction using Fusion High-Fidelity PCR Master Mix kit (NEB, M0531S) and specific index primers supplied in NEBNext Multiplex Oligo Kit for Illumina (Index Primer Set 1, NEB, E7335L).', {'entities': [(209, 217, 'platform')]}),
 (' Samples with proper size (250–300\xa0bp) were selected for next generation sequencing using Illumina Hiseq 2000 or 2500 platform.', {'entities': [(90, 98, 'platform')]}),
 (' Samples with appropriate nucleosomal laddering profiles were selected for next generation sequencing using Illumina Hiseq 2500 platform.', {'entities': [(108, 116, 'platform')]}),
 (' Thus, control genotypes were selected from existing datasets matched as closely as possible to the ancestry of cases and Illumina arrays as similar as possible to the 660W array ().', {'entities': [(122, 130, 'platform')]}),
 (" For Stage 1, genotyping was performed at the Center for Applied Genomics at The Children's Hospital of Philadelphia, using the Illumina Infinium™ II HumanHap550K (V3), as previously described ().", {'entities': [(128, 136, 'platform')]}),
 (' We genotyped 8444 case samples using the multiplex PCR-based Invader assay and 26\u2009659 control samples using the Illumina Human610-Quad BeadChip.', {'entities': [(113, 121, 'platform')]}),
 (' That between the Illumina Human610-Quad BeadChip and the HumanOmniExpress BeadChip was 0.999 among 780 duplicate samples.', {'entities': [(18, 26, 'platform')]}),
 (' Also, the concordance rate between genotype data of the multiplex PCR-based Invader assay and those of the Illumina Human610-Quad BeadChip was 0.994 (8797/8852 genotypings in 6 SNPs).', {'entities': [(108, 116, 'platform')]}),
 ('For stage 1, genome-wide genotyping was performed using the Illumina 610K Quad BeadChip, following the manufacturer’s instructions (see URLs).', {'entities': [(60, 68, 'platform')]}),
 (' Illumina and Sequenom cluster plots are shown in , respectively, for the SNPs surpassing the formal threshold for genome-wide significance (P  < 5 × 10_−8 ): rs11024012 (PLEKHA7 ), rs3753841 (COL11A1 ) and rs1015213 (chromosome 8q).', {'entities': [(1, 9, 'platform')]}),
 (' The signal intensity data were converted into genotypes using Illumina Beadstudio 2.0 software.', {'entities': [(63, 71, 'platform')]}),
 (' The dataset was genotyped with Illumina human 670K chip in Wellcome Trust Sanger Institute.', {'entities': [(32, 40, 'platform')]}),
 (' Dataset was genotyped in at the SNP Technology Platform in Uppsala University with Illumina OmniExpress 700K chip.', {'entities': [(84, 92, 'platform')]}),
 ('Genotyping of the complete dataset was performed at the Illumina facilities using the Sentrix® HumanHap550 BeadChip.', {'entities': [(56, 64, 'platform')]}),
 (' A total of 1024 HANDLS participants were genotyped using the Illumina 1 m SNP array, including 329 AAs with iron measures.', {'entities': [(62, 70, 'platform')]}),
 (' Over half of the more than 700,000 SNPs on the IlluminaOmniExpress BeadChip reside within 10 Kb of a RefSeq gene, while only about 15,000 are predicted to cause a non-synonymous amino acid change.', {'entities': [(48, 56, 'platform')]}),
 (' RNA sequencing was performed using the Illumina HiSeq2000 next generation sequencing platform.', {'entities': [(40, 48, 'platform')]}),
 (' Briefly, samples were genotyped on either the Illumina HumanHap 650Y or 1M-Duo platform.', {'entities': [(47, 55, 'platform')]}),
 (' The NABEC is comprised of 304 neurologically normal donors from the National Institute of Ageing and expression profiled on the Illumina HT12v3 array.', {'entities': [(129, 137, 'platform')]}),
 (' The ULSAM samples were genotyped using the Illumina Omni2.5M platform.', {'entities': [(44, 52, 'platform')]}),
 (' The\nEUGENE2 samples were genotyped using the Illumina 550K platform.', {'entities': [(46, 54, 'platform')]}),
 (' DNA samples were genotyped using the Illumina 317, 370 and 610 SNP chips.', {'entities': [(38, 46, 'platform')]}),
 ('DNA samples from the 79 subjects enrolled into the Florida-2 cohort were genotyped using the Illumina HumanOmni2.5-Quad (Omni2.', {'entities': [(93, 101, 'platform')]}),
 (' Briefly, genotyping was performed using the Illumina HumanOmniExpress, with imputation based on the 1,000 Genomes Phase I v3 reference panel.', {'entities': [(45, 53, 'platform')]}),
 (' Genotypes on 550K Illumina Human Beadchip were available for the validation data set [AGRE, 2008].', {'entities': [(19, 27, 'platform')]}),
 (' Samples were genotyped using Illumina’s Human 1M Beadchip, containing 1,072,820 SNPs.', {'entities': [(30, 38, 'platform')]}),
 (' WHI Questions on Urinary Incontinence The GARNET study genotyped 4,894 women with the Illumina Omni Quad 1.0M chip.', {'entities': [(87, 95, 'platform')]}),
 (' DNA samples were genotyped using the Illumina Human660W-Quad v1 BeadChips assays [].', {'entities': [(38, 46, 'platform')]}),
 (' Genotypes were determined using Illumina chips; methods, QC steps and imputation of untyped HapMap 2 SNPs were as previously described ().', {'entities': [(33, 41, 'platform')]}),
 (' Ten thousand and fifteen women (mothers from the ALSPAC cohort) were genotyped using the Illumina 660 quad SNP chip which contains 557 124 SNP markers.', {'entities': [(90, 98, 'platform')]}),
 (' Due to technical restrictions, genome-wide analysis of the pooled DNAs was performed only with the Illumina HumanHap300 (317k) BeadChip.', {'entities': [(100, 108, 'platform')]}),
 (" This method was recently proved valid in several studies including case/control studies in late-onset Alzheimer's disease and in schizophrenia, and a comparison with individual genotyping revealed excellent concordance for the Illumina HumanHap300 array.", {'entities': [(228, 236, 'platform')]}),
 ('0%] was examined by Illumina HumanOmni1-Quad BeadChip GWAS array at Korea National Institute of Health.', {'entities': [(20, 28, 'platform')]}),
 (' For stage 1, 492 samples from GPA cases and 382 from historical controls were genotyped using Illumina HumanHap370 BeadChips.', {'entities': [(95, 103, 'platform')]}),
 (' Anderson Cancer Center Lung Cancer Study were genotyped at the Johns Hopkins University Center for Inherited Disease Research, using Illumina HumanHap300 v1.1 BeadChips.', {'entities': [(134, 142, 'platform')]}),
 (' Each SNP was determined using Illumina Genome Studio version 2010.3 with Genotyping Module version 1.', {'entities': [(31, 39, 'platform')]}),
 (' Demographic and Clinical Characteristics of 983 AD PatientsSamples were genotyped using the Illumina Omni1-Quad chip as described previously [, ].', {'entities': [(93, 101, 'platform')]}),
 (' Illumina exome array genotyping was available for 95% of the patients in the combined patient cohort (supplemental Table 1).', {'entities': [(1, 9, 'platform')]}),
 (' We analyzed 193 normal human cortex cells using Illumina HumanRef-seq-8 Expression BeadChip arrays.', {'entities': [(49, 57, 'platform')]}),
 (' Genome-wide genotype data on 1,221 subjects from Illumina Human-1M-Duo were from a separate immunogenomics project [].', {'entities': [(50, 58, 'platform')]}),
 (' Approximately 10% of the Icelandic case samples that were genotyped on the Illumina platform were also genotyped using the Centaurus assays and the observed mismatch rate was lower than 0.5%.', {'entities': [(76, 84, 'platform')]}),
 ('5–4v1-H BeadChip (Illumina, San Diego, CA) was used to genotype 2,450,000 SNPs in 1200 Caucasian smokers from the LSC.', {'entities': [(18, 26, 'platform')]}),
 (' PEGASUS included 4,599 PCa cases and 2,940 controls of non-Hispanic white race/ethnicity, genotyped using Illumina HumanOmni2.5 and imputed using 1000 Genomes Project Phase I data (1,092 individuals).', {'entities': [(107, 115, 'platform')]}),
 (' MEC included 2,265 cases and 2,414 controls of African-American race/ethnicity, genotyped using the Illumina Infinium 1MDuo (dbGap phs000306.v3.', {'entities': [(101, 109, 'platform')]}),
 (' Surgical hematoxylin and eosin (H&E) sections from fresh frozen materials were reviewed to identify normal (non-cancerous) tissue samples and RNA-seq data was obtained with an Illumina HiSeq 2000. The second eQTL analysis included prostate tumor tissue samples from 99 men and normal prostate tissue from 56 men with incident PCa who participated in the Physicians’ Health Study (PHS) and Health Professionals Follow-up Study (HPFS) (NCBI GEO GSE62872) () using genotype data from the Breast and Prostate Cancer Cohort Consortium (BPC3) aggressive PCa GWAS ().', {'entities': [(177, 185, 'platform')]}),
 (' The concordance rate of genotypes derived from the two genotyping platforms (Illumina and Centaurus) was >99.5%.', {'entities': [(78, 86, 'platform')]}),
 ('5-4v1-H BeadChip (Illumina, San Diego, CA) was used to genotype 2 450 000 SNPs in 1200 white smokers from the LSC.', {'entities': [(18, 26, 'platform')]}),
 ('Genomic DNA samples were genotyped using the Illumina (San Diego, CA) Human660W-Quad v.', {'entities': [(45, 53, 'platform')]}),
 (' To ensure the harmonisation of genotype calling between HEBCS and POSH GWS, the HEBCS GWS intensity files were processed with Illumina’s Genome Studio software to call genotypes consistently with the POSH genotypes using a GenCall threshold of 0.15.', {'entities': [(127, 135, 'platform')]}),
 (' The SUCCESS-A GWAS was genotyped on the Illumina HumanOmniExpress-12v1 G FFPE array.', {'entities': [(41, 49, 'platform')]}),
 ('Germline DNA of 183 cancer patients treated with monotherapy paclitaxel stored in Biobank Japan (University of Tokyo) were genotyped using Illumina OmniExpress BeadChip that contained 733,202 SNPs ().', {'entities': [(139, 147, 'platform')]}),
 (' We genotyped all subjects on Illumina platforms and imputed genotypes using MaCH and minimac () with 1,000 Genomes Phase I v3 reference panels.', {'entities': [(30, 38, 'platform')]}),
 (' The Illumina Exome Chip, Omni1-Quad, 1M-Duo, and Human660W-Quad BeadChip Arrays were used for the Vanderbilt BioVU cohort.', {'entities': [(5, 13, 'platform')]}),
 (' The Australian replication collection had GWAS genotyping on all cases and controls using Illumina genome-wide arrays, and CACNA1A  rs4926244 was directly genotyped from the GWAS arrays.', {'entities': [(91, 99, 'platform')]}),
 (' Demographic, dietary PUFA intake (presented as means and SDs) and fatty acid levels (presented as means of % fatty acid subtype from total plasma fatty acids) in the SCHS studyGenome-wide genotyping was performed for SCHS samples using the Illumina HumanOmni ZhongHua-8 Bead Chip.', {'entities': [(241, 249, 'platform')]}),
 ('A pilot study of 81 MM samples used an Illumina 660 array genotyped at the UCSF Genomics Core Facility.', {'entities': [(39, 47, 'platform')]}),
 (' In a second phase, we genotyped 289 MM samples using an Illumina Omni5 array at Expression Analysis (Durham, NC).', {'entities': [(57, 65, 'platform')]}),
 (' Briefly, genotyping was performed per manufacturer’s protocol using blood genomic DNA samples and Illumina GWAS arrays (610-Quad, OmniExpress, or HumanOmni2.5-4v1).', {'entities': [(99, 107, 'platform')]}),
 (' Sequencing was performed using the Illumina HiSeq2000 system through paired-end read chemistry and read lengths of 100 base pairs.', {'entities': [(36, 44, 'platform')]}),
 (' Participants with poor quality variant calls (concordance rate < 99% for SNPs genotyped through both sequencing and the Illumina HumanOmni2.5-4v1 array) were excluded from further analysis.', {'entities': [(121, 129, 'platform')]}),
 (' Briefly genotypes were generated using the Illumina Infinium HumanHap550 array, and we only used genotypes with a call rate of >97%.', {'entities': [(44, 52, 'platform')]}),
 (' Lymphocyte RNA was isolated and anti-sense RNA was synthesized, amplified, purified and hybridized to Illumina BeadChips version 3 according to standard protocols.', {'entities': [(103, 111, 'platform')]}),
 (' Significantly expressed probes were identified as follows: (1) for each probe, samples were classified as significantly or not significantly expressed at a "detection p-value" (which is defined by the Illumina software based on comparisons with null probes) of p <= 0.05; (2) for each probe, binomial tests were conducted on the number of samples in which the probes was "detected" or "not detected"; and (3) finally, considering all p-values resulting from the binomial tests for all probes, probes were accepted to be significantly expressed at a 5% false-discovery rate (FDR).', {'entities': [(202, 210, 'platform')]}),
 (' Genotyping was carried out using Illumina arrays containing a common set of about 575,000 genotyped SNPs.', {'entities': [(34, 42, 'platform')]}),
 (' All genotypes for this project were called centrally using Illumina Genome Studio and all 3759 SNPs of interest for FTD were manually examined to ensure high-quality genotype clusters before data export.', {'entities': [(60, 68, 'platform')]}),
 ('Genotyping was carried out using three genotyping platforms from Illumina: the HumanHap 300k Duo for part of the UK Twin Cohort and the HumanHap610-Quad array for the rest of the UK Twin Cohort.', {'entities': [(65, 73, 'platform')]}),
 (' Illumina’s Human1M-Duo chip was used for genotyping of the 1958 British Birth Cohort.', {'entities': [(1, 9, 'platform')]}),
 (' Genotyping of autosomal SNPs was performed in persons with high quality extracted DNA (n  = 6,449) using the Illumina Infinium II HumanHap550 chip v3.0 array according to the manufacturer’s protocols.', {'entities': [(110, 118, 'platform')]}),
 (' In the RS-III cohort, all DNA samples were genotyped using the Illumina Infinium II HumanHap550 chip v3.0 array.', {'entities': [(64, 72, 'platform')]}),
 (' Genotyping of autosomal SNPs was performed in persons with high quality extracted DNA (n  = 6,449) using the Illumina Infinium II HumanHap550 chip v3.0 array according to the manufacturer’s protocols.', {'entities': [(110, 118, 'platform')]}),
 (' In the RS-III cohort, all DNA samples were genotyped using the Illumina Infinium II HumanHap550 chip v3.0 array.', {'entities': [(64, 72, 'platform')]}),
 (' Replication controls consisted of 2583 Ashkenazi schizophrenia cases and controls from the North Shore-Long Island Jewish Health System typed on Illumina HumanOmni1-Quad BeadChip, imputed using the same procedure and passing the same quality control and ancestry filtering as the discovery cohort.', {'entities': [(146, 154, 'platform')]}),
 (' Genotyping was performed using the Illumina HumanCytoSNP-12 BeadChip utilizing 250 ng DNA according to the manufacturer’s protocol.', {'entities': [(36, 44, 'platform')]}),
 (' cRNA synthesis was done from 250 ng of RNA using Illumina TotalPrep 96 RNA Amplification kit.', {'entities': [(50, 58, 'platform')]}),
 (' Gene expression was measured using the Illumina HumanHT-12-v4 BeadChip utilizing 750 ng of cRNA according to the manufacturer’s protocol.', {'entities': [(40, 48, 'platform')]}),
 ('DNA samples were prepared using strict quality control procedures and genotyped using the Illumina HumanOmni2.5 array.', {'entities': [(90, 98, 'platform')]}),
 (' The VQ, UK1 and Scotland1 GWA cohorts were genotyped using Illumina Hap300, Hap240S, Hap370 or Hap550 arrays.', {'entities': [(60, 68, 'platform')]}),
 (' The CCFR samples were genotyped using Illumina Hap1M, Hap1M-Duo or Omni-express arrays.', {'entities': [(39, 47, 'platform')]}),
 (' CGEMS samples were genotyped using Illumina Hap300 and Hap240 or Hap550 arrays.', {'entities': [(36, 44, 'platform')]}),
 (' In addition, in silico  genotypes were obtained from Illumina beadchip data for 1,838 sporadic ALS patients and 1,697 controls from Italy.', {'entities': [(54, 62, 'platform')]}),
 (' For the Italian SLAGEN cohort, in silico  genotypes were obtained from Illumina Human-660W Quad Beadchips for rs12546767, and rs13268726 genotypes were imputed using IMPUTE v2 and HapMap3 release 2 and 1000 Genomes pilot reference panels.', {'entities': [(72, 80, 'platform')]}),
 (' Expression was assessed using Illumina Whole-Genome Expression Beadchips (HumanHT-12 v4).', {'entities': [(31, 39, 'platform')]}),
 ('Genotyping for PREVEND and Lifelines was performed on the Illumina CytoSNP12 v2 chip.', {'entities': [(58, 66, 'platform')]}),
 ('  We performed genotyping in the breast cancer GWAS in NHS using the Illumina HumanHap550 array, as part of the National Cancer Institute’s Cancer Genetic Markers of Susceptibility Project.', {'entities': [(69, 77, 'platform')]}),
 (' For the glaucoma GWAS, we performed genotyping using the Illumina HumanHap660 array.', {'entities': [(58, 66, 'platform')]}),
 (' For the kidney stone, advanced prostate cancer, and melanoma GWASs, we performed genotyping using the Illumina HumanHap610 array.', {'entities': [(103, 111, 'platform')]}),
 ('  We performed genotyping in the breast cancer GWAS in NHS using the Illumina HumanHap550 array, as part of the National Cancer Institute’s Cancer Genetic Markers of Susceptibility Project.', {'entities': [(69, 77, 'platform')]}),
 (' For the glaucoma GWAS, we performed genotyping using the Illumina HumanHap660 array.', {'entities': [(58, 66, 'platform')]}),
 (' For the kidney stone, advanced prostate cancer, and melanoma GWASs, we performed genotyping using the Illumina HumanHap610 array.', {'entities': [(103, 111, 'platform')]}),
 (' All samples were genotyped on the Illumina Cyto12 array version 2-1 at the Yale Center for Genome Analysis, and called in GenomeStudio software V2011.1 using genotyping module version 1.', {'entities': [(35, 43, 'platform')]}),
 (' Genotype clustering was performed using the default Illumina cluster file (Immunochip_Gentrain_ June2010.egt) and manifest file (Immuno_ BeadChip_11419691.', {'entities': [(53, 61, 'platform')]}),
 (' Genotype clustering was performed using the default Illumina cluster file (Immunochip_Gentrain_ June2010.egt) and manifest file (Immuno_ BeadChip_11419691.', {'entities': [(53, 61, 'platform')]}),
 ('Additional SNPs at the 9q33 loci, not genotyped on the Illumina SNP bead-chips, were imputed with the IMPUTE software using the HapMap CEU data set (version 22) as training set.', {'entities': [(55, 63, 'platform')]}),
 (' Gene expression was measured using the Illumina HumanHT-12v4 Expression BeadChip at the Channing Division of Network Medicine, using similar methods to those described previously ().', {'entities': [(40, 48, 'platform')]}),
 ('The majority (N=587) of CAP self-reported Caucasians were genotyped using the Illumina HumanHap300 (N=305) or HumanHap610-Quad (N=282) beadchips as previously described [].', {'entities': [(78, 86, 'platform')]}),
 ('GCD GWAS samples were genotyped on the Illumina HumanOmni1-Quad v1.0 microarray containing 988 306 autosomal SNPs, at the Center for Inherited Disease Research (CIDR) and the Yale Center for Genome Analysis.', {'entities': [(39, 47, 'platform')]}),
 (' The SAGE samples were genotyped on the Illumina Human 1 M array containing 1 069 796 total SNPs.', {'entities': [(40, 48, 'platform')]}),
 (' Follow-up genotyping in the replication sample was performed using a custom Illumina GoldenGate Genotyping Universal-32, 1536-plex microarray.', {'entities': [(77, 85, 'platform')]}),
 (' compared the transcriptomes of brains from alcohol-dependent subjects to those of brains from control subjects using the Illumina HumanHT-12 expression array, focusing on three different brain regions: the central nucleus (CNA) and basolateral nucleus (BLA) of the amygdala and the superior frontal cortex (CTX).', {'entities': [(122, 130, 'platform')]}),
 (' DNA samples were genotyped on ~1M SNPs using the Illumina Omni1-Quad platform.', {'entities': [(50, 58, 'platform')]}),
 (' Genotyping was performed on the Illumina Omni-1Quad platform with QC parameters as described above.', {'entities': [(33, 41, 'platform')]}),
 (" The Stage II studies included a total of 47 791 individuals and consisted of de novo  genotyping data from three study sites and in silico  replication data from the Tai Chi study, which had been previously genotyped with Illumina's iSelect 200k Cardio-MetaboChip (Supplementary Material, Table S3).", {'entities': [(223, 231, 'platform')]}),
 (' Internal sets (HKS, SNU, CNULCS, SWHS, YLCS and components of samples from Japan and GELAC) were genotyped at the NCI Cancer Genomic Research (CGR) Laboratory using the Illumina 660W SNP microarray.', {'entities': [(170, 178, 'platform')]}),
 (' in Beijing using the Illumina 660W SNP microarray; b) samples from GELAC were genotyped on contract at GeneTech Biotech Co.', {'entities': [(22, 30, 'platform')]}),
 (' The scanned intensity data from external sources were collected, and genotypes were clustered and called at the CGR using Illumina Genome Studio v2011.1 on the basis of the GenTrain2 calling algorithm.', {'entities': [(123, 131, 'platform')]}),
 (' Genotyping was attempted for a total of 5,568 samples on the Illumina 660W SNP microarray at the CGR.', {'entities': [(62, 70, 'platform')]}),
 (' Six samples could not be loaded into the Illumina Genome Studio because of their low intensities, and 16 samples failed to scan because of broken chips.', {'entities': [(42, 50, 'platform')]}),
 (' In an analysis of 385 samples from 7 studies, the comparison of the Illumina calls with the TaqMan assays conducted at the NCI CGR showed an average concordance rate of 99.97% (with a range of 99.', {'entities': [(69, 77, 'platform')]}),
 (' The comparison of the Illumina calls with the TaqMan assays showed an average concordance rate of 99.93% (with a range of 99.', {'entities': [(23, 31, 'platform')]}),
 (' For the replication phase, we analyzed an additional 3,933 individuals (1,023 cases and 2,910 controls) with TaqMan data, and an additional 79 individuals (76 cases and 3 controls) genotyped using the Illumina 660W array at Gene-Square were available for analysis.', {'entities': [(202, 210, 'platform')]}),
 (' Genomewide genotyping was performed by the Center for Inherited Disease Research at\nJohns Hopkins University using the Illumina Omni2.5 microarray (www.', {'entities': [(120, 128, 'platform')]}),
 (' To evaluate the relative expression of implicated genes in a variety of human tissues, we used RNA-Seq data from the Illumina Human BodyMap 2.0 project ().', {'entities': [(118, 126, 'platform')]}),
 ('[] Genotyping was performed using the Illumina Human1M-Duo BeadChip array.', {'entities': [(38, 46, 'platform')]}),
 ('Our initial sample consisted of 1,817 DSM-IV OCD cases, 504 controls and 663 complete trios, genotyped using the\nIllumina Human610-Quadv1_B SNP array.', {'entities': [(113, 121, 'platform')]}),
 ('DNA samples from both the GABC and TSS cohorts were genotyped using the Illumina HumanOmni1-Quad_v1-0_B array.', {'entities': [(72, 80, 'platform')]}),
 (' Data were genotyped using the Illumina Human660W-Quad array (, for details).', {'entities': [(31, 39, 'platform')]}),
 ('The Bonn1CSF sample was genotyped on the Illumina 610-quad chip, and was part of the sample investigated by Harold et al .', {'entities': [(41, 49, 'platform')]}),
 (' The Bonn2CSF sample was genotyped using the Illumina Omni 1M-quad chip.', {'entities': [(45, 53, 'platform')]}),
 (' The ADNI cohort was genotyped using the Illumina 610 chip.', {'entities': [(41, 49, 'platform')]}),
 (' The control sample of Bonn1 was genotyped using the Illumina HumanHap550k chip.', {'entities': [(53, 61, 'platform')]}),
 (' The control sample of Bonn2 was genotyped with the Illumina 1M-quad chip.', {'entities': [(52, 60, 'platform')]}),
 (' The three GWAS used include the following: set I, samples genotyped using Illumina HumanHap550v1 as described by Hom et al .', {'entities': [(75, 83, 'platform')]}),
 ('; set II, samples genotyped using Illumina HumanHap300 as described by Harley et al .', {'entities': [(34, 42, 'platform')]}),
 (' For the GWAS, 592 232 SNPs were genotyped using Illumina HumanHap610-Quad Genotyping BeadChip.', {'entities': [(49, 57, 'platform')]}),
 (' SNPs not on the Illumina array were imputed using minimac  () with reference CEU haplotypes from 1000 Genomes (2/2012) after having been prephased with BEAGLE  ().', {'entities': [(17, 25, 'platform')]}),
 (' Although not on the Illumina array, these two SNPs could be imputed relatively accurately with reference to haplotypes in the 1000 Genomes reference panel, with imputation r_2  values of .', {'entities': [(21, 29, 'platform')]}),
 (' SNPs not on the Illumina array were imputed using minimac  () with reference CEU haplotypes from 1000 Genomes (2/2012) after having been prephased with BEAGLE  ().', {'entities': [(17, 25, 'platform')]}),
 (' Although not on the Illumina array, these two SNPs could be imputed relatively accurately with reference to haplotypes in the 1000 Genomes reference panel, with imputation r_2  values of .', {'entities': [(21, 29, 'platform')]}),
 (' MECC DNA was genotyped in two batches using the Illumina HumanOmni 2.5–8 BeadChip, which measures nearly 2.', {'entities': [(49, 57, 'platform')]}),
 (' Briefly, 20,776 samples were genotyped with Illumina (550K, 610K, 660K or OmniExpress) arrays, and standard quality control (QC) filters were applied before imputation.', {'entities': [(45, 53, 'platform')]}),
 ('A total of 2,418 current smokers were genotyped using the Illumina Human1M-Duo BeadChip (1,199,187 SNPs).', {'entities': [(58, 66, 'platform')]}),
 ('The DNA from the CSSCD, Walk-PHaSST, PUSH and Hong Kong samples were genotyped using the Illumina Human610-Quad array and processed and analyzed as described.', {'entities': [(89, 97, 'platform')]}),
 (' Genome-wide genotyping of cases was performed on the Illumina 610 quad platform.', {'entities': [(54, 62, 'platform')]}),
 (' Genome-wide genotyping of controls was performed on the Illumina HumanHap 550K v3 platform.', {'entities': [(57, 65, 'platform')]}),
 (' We calculated the concordance rates of the five SNPs in  between genotypes determined by the Illumina HumanHap610-Quad BeadChip and those determined by the TaqMan assay (rs1837253, rs10508372 and rs1701704) or multiplex-PCR based Invader assay (rs7686660 and rs404860).', {'entities': [(94, 102, 'platform')]}),
 (' Genotyping was performed with Illumina chips and >2.5 million SNPs were imputed from HapMap data.', {'entities': [(31, 39, 'platform')]}),
 ('Genotyping of cases in the GWAS was performed on the Illumina HumanCNV370-duo Bead array.', {'entities': [(53, 61, 'platform')]}),
 (' We utilised data on controls from the 1958BC and NBS which had been genotyped on the Illumina Infinium 1.2M array at the Wellcome Trust Sanger Institute.', {'entities': [(86, 94, 'platform')]}),
 (' We performed cross-platform validation, genotyping by Taqman 283 samples that had been run on the Illumina array (concordance 97.8 %).', {'entities': [(99, 107, 'platform')]}),
 (' Expression analysis was performed using Illumina HumanRef-8 Expression BeadChips, and SNP genotyping was performed using Infinium HumanHap550 BeadChips.', {'entities': [(41, 49, 'platform')]}),
 (' Genotyping of the complete Dutch GWAS sample was performed at the Wellcome Trust Sanger Institute using the Illumina 660W technology.', {'entities': [(109, 117, 'platform')]}),
 ('Sequencing was performed using a Genome Analyser-2 platform (Illumina) at the Beijing Genomics Institute, with library preparation and a 91bp paired-end sequencing strategy, according to manufacturer’s instructions.', {'entities': [(61, 69, 'platform')]}),
 (' The HapMap3 resource (Stranger et al, under review) comprises LCLs from 726 HapMap3 individuals (CEU: 109, CHB: 80, GIH: 82, JPT: 82, LWK: 82, MEX: 45, MKK: 138, and YRI: 108), with mRNA transcript levels measured using Illumina’s whole genome expression array Sentrix Human-6 Expression BeadChip version 2. Log2 transformed expression signals were normalized as follows: quantile normalization across replicates of a single individual, followed by median normalization across all individuals of the eight populations.', {'entities': [(221, 229, 'platform')]}),
 (' Genotyping was done with a combination of Illumina arrays (HumanHap300, HumanHap610Q, 1MDuo and 1.2MDuo).', {'entities': [(43, 51, 'platform')]}),
 (' The subset used here includes individuals typed withthe 610K-quad chip(1138 individuals); 370K or 370K-duo chips (738 individuals); or the Illumina 317K chip (644 individuals); 316 individuals were genotyped on more than one chip either for deliberate QC reasons or to obtain highercoverage than an early generation chip used previously.', {'entities': [(140, 148, 'platform')]}),
 ('The GCTA program as described by Yang and colleagues () was used to estimate the proportion of phenotypic variance for maxdrinks explained by the genome-wide SNPs genotyped on the Illumina 1M chip in the SAGE dataset.', {'entities': [(180, 188, 'platform')]}),
 (' For the majority of the 1 475 subjects genotyped on one chip (N=1 286; 87%), genotyping was part of the NTR2 genotyping study using the Illumina Human660W-Quad chip.', {'entities': [(137, 145, 'platform')]}),
 (' We included 476 individuals (56% females) with GWA data (Illumina HumanHap300 chip) in this study.', {'entities': [(58, 66, 'platform')]}),
 (' For the majority of the 1 475 subjects genotyped on one chip (N=1 286; 87%), genotyping was part of the NTR2 genotyping study using the Illumina Human660W-Quad chip.', {'entities': [(137, 145, 'platform')]}),
 (' We included 476 individuals (56% females) with GWA data (Illumina HumanHap300 chip) in this study.', {'entities': [(58, 66, 'platform')]}),
 ('Genotyping of the FinnDiane patients was performed using the Illumina 610Quad chip; genotype calling, quality control, and imputation procedures have been described earlier.', {'entities': [(61, 69, 'platform')]}),
 (' Illumina HumanHap550v3 Genotyping BeadChip was used for stage 1 of the GWAS.', {'entities': [(1, 9, 'platform')]}),
 (' All 405 children and their parents were genotyped using the Illumina Sentrix Human-1 Genotyping BeadChip.', {'entities': [(61, 69, 'platform')]}),
 ('DNA specimens from 219 phase 1 participants (107 AD cases, 112 age-matched cognitively normal controls) and from 88 phase 2 participants (37 AD cases, 51 controls) were genotyped with the Illumina Hap300 (ver.', {'entities': [(188, 196, 'platform')]}),
 ('The Illumina Human CNV370-Duo DNA Bead Chip was used for genotyping DNA family members of the UMN Study.', {'entities': [(4, 12, 'platform')]}),
 (' In general, we considered only SNPs with an Illumina design score of 0.8 or greater (some OCAC and CIMBA SNPs with lower design scores were included).', {'entities': [(45, 53, 'platform')]}),
 (' Where possible, preference was given to SNPs previously genotyped by Illumina (design score = 1.1).', {'entities': [(70, 78, 'platform')]}),
 ('  Genotyping of the TwinsUK dataset was done with a combination of Illumina arrays (HumanHap300, HumanHap610Q, 1M-Duo and 1.2MDuo 1M) _, .', {'entities': [(67, 75, 'platform')]}),
 ('  Genotyping of the TwinsUK dataset was done with a combination of Illumina arrays (HumanHap300, HumanHap610Q, 1M-Duo and 1.2MDuo 1M) _, .', {'entities': [(67, 75, 'platform')]}),
 (' Genotyping of the TwinsUK dataset was done with a combination of Illumina arrays (HumanHap300, HumanHap610Q, 1M-Duo and 1.2MDuo 1M) _, .', {'entities': [(66, 74, 'platform')]}),
 ('All of the contributed samples were genotyped on 1 of the Illumina (San Diego, CA, USA) single nucleotide polymorphism (SNP) chips (see ); 254,145 SNPs common across the various SNP genotyping arrays and that passed quality control were analyzed in these cohorts.', {'entities': [(58, 66, 'platform')]}),
 ('The UK samples were genotyped at the Wellcome Trust Sanger Institute on Illumina 660. QC of samples was based on the following criteria, with inclusion/exclusion thresholds for each determined empirically: samples were removed if they displayed heterozygosity outside the interval [0.', {'entities': [(72, 80, 'platform')]}),
 ('The Illumina 660 chip interrogates genotype values for 594 398 SNPs.', {'entities': [(4, 12, 'platform')]}),
 (' individuals on the basis of genotype data sets previously generated on Illumina Human CNV370-Duo arrays_, .', {'entities': [(72, 80, 'platform')]}),
 (' As previously described (,), genotyping was performed in patients of European ancestry at the Center for Genotyping and Analysis at the Broad Institute (MAYO, VUMC, and NU) and the Center for Inherited Disease Research at the Johns Hopkins University (MC and GHC) using the Illumina Human660W-Quadv1_A genotyping platform, consisting of 561,490 SNPs and 95,876 intensity-only probes.', {'entities': [(275, 283, 'platform')]}),
 (' Of the 56 SNPs associated with PLT, 23 were genotyped on the Illumina 660W platform used in the eMERGE network.', {'entities': [(62, 70, 'platform')]}),
 (' A total of 16,732 SNPs exhibiting an Illumina score superior or equal to 0.4 were selected for microarray production.', {'entities': [(38, 46, 'platform')]}),
 (' During the Illumina production process, 2,287 SNPs failed oligonucleotide synthesis, leading to a final number of 14,445 SNPs for which genotyping was attempted.', {'entities': [(12, 20, 'platform')]}),
 (' MMAP samples obtained from dbGaP were genotyped on the Illumina HumanCNV370v1 Bead Array (ILMN 370, 370404 SNPs).', {'entities': [(56, 64, 'platform')]}),
 (' MMAP samples obtained from dbGaP were genotyped on the Illumina HumanCNV370v1 Bead Array (ILMN 370, 370404 SNPs).', {'entities': [(56, 64, 'platform')]}),
 (' 1504 samples were attempted at CGR on the Illumina HumanHap660 chips for NCI-GWAS2. The 1504 bladder cancer case samples, mapped to 1483 unique individuals from seven studies: HPFS, BBCS, FBCS, CeRePP, WHI, LABCS and NHS I and II.', {'entities': [(43, 51, 'platform')]}),
 (' In addition, 742 samples from NEBCS-NH were genotyped on Illumina HumanHap610 chip at the CGR, mapping to 720 unique individuals.', {'entities': [(58, 66, 'platform')]}),
 (' The Illumina Infinium cluster plots for the four novel associations, rs10936599 at 3q26.2, rs907611 at 11p15.', {'entities': [(5, 13, 'platform')]}),
 (' SNP genotypes for twins were determined with a combination of Illumina arrays (HumanHap300(; ), HumanHap610Q, 1\u2009M-Duo and 1.2MDuo 1\u2009M).', {'entities': [(63, 71, 'platform')]}),
 (' UK controls were taken from the available data from The Wellcome Trust Case-Control Consortium (WTCCC 1958 birth cohort on the Illumina Human1M-Duo v3 BeadChip (n = 2415; http://www.', {'entities': [(128, 136, 'platform')]}),
 (' Swedish and Dutch controls (n = 642) were taken from previously published datasets [], and Spanish controls (n = 259) were obtained from blood bank volunteers in Granada, Spain using data generated on the Illumina Human1M-Duo v3 BeadChip.', {'entities': [(206, 214, 'platform')]}),
 (", San\nDiego, CA) or Illumina's Infinium HD Human610-Quad BeadChip at the Channing\nLaboratory.", {'entities': [(20, 28, 'platform')]}),
 (' Genotyping of LOCCS was conducted at the Riken Center for Genomic\nMedicine using the Illumina Infinium HD Human610-Quad BeadChip.', {'entities': [(86, 94, 'platform')]}),
 (' Genotypic data from LLFS blood assays using the Illumina Human Omni 2.5 v1 chips were produced by the Center for Inherited Disease Research (CIDR).', {'entities': [(49, 57, 'platform')]}),
 (' In the HABC, genotyping was performed by the Center for Inherited Disease Research using the Illumina Human1M-Duo BeadChip system.', {'entities': [(94, 102, 'platform')]}),
 (' A sample of 941 GENDER subjects was genotyped on the Illumina Human 610-Quad Beadchips.', {'entities': [(54, 62, 'platform')]}),
 (' A sample of 941 GENDER subjects was genotyped on the Illumina Human 610-Quad Beadchips.', {'entities': [(54, 62, 'platform')]}),
 ('Genome-wide genotyping of SNPs on the 515 AGNES cases and 457 AGNES controls was done using the Illumina Human610-Quad v1 array.', {'entities': [(96, 104, 'platform')]}),
 ('33 using the cluster file provided by Illumina (Human610-Quadv1_B.', {'entities': [(38, 46, 'platform')]}),
 (' For GENDER-MI, genotypes at rs2824292, rs1353342 and rs12090554 were extracted from previously obtained genotypes using the Illumina Human 610-Quad Beadchip.', {'entities': [(125, 133, 'platform')]}),
 ('0 in\xa0GERFHS and with Illumina HumanHap610-Quad in GOCHA and ESs.', {'entities': [(21, 29, 'platform')]}),
 (' The AMD-MMAP samples were genotyped at CIDR using the Illumina CNV370v1_C array.', {'entities': [(55, 63, 'platform')]}),
 (' The sample of 378 i/fPAH patients and 1,140 healthy controls were typed with the Illumina Human 610-Quad Beadchip.', {'entities': [(82, 90, 'platform')]}),
 (' The sample of 378 i/fPAH patients and 1,140 healthy controls were typed with the Illumina Human 610-Quad Beadchip.', {'entities': [(82, 90, 'platform')]}),
 (' The sample of 378 i/fPAH patients and 1,140 healthy controls were typed with the Illumina Human 610-Quad Beadchip.', {'entities': [(82, 90, 'platform')]}),
 (' Specifically, we used Illumina SNP arrays to genotype 3523 EOBC cases and 2702 control women and to impute their genotypes for the HaMap3 SNPs (hereafter called the discovery set ).', {'entities': [(23, 31, 'platform')]}),
 ('org) using the Illumina Human1M and HumanOmni1-Quad BeadChips.', {'entities': [(15, 23, 'platform')]}),
 ('org) using the Illumina Human1M and HumanOmni1-Quad BeadChips.', {'entities': [(15, 23, 'platform')]}),
 ('Samples for Phase 1 were genotyped on the Illumina HumanOmni1-Quad v1.0 microarray containing 988,306 autosomal SNPs, at the Center for Inherited Disease Research (CIDR) and the Yale Center for Genome Analysis.', {'entities': [(42, 50, 'platform')]}),
 (' Follow-up genotyping (Phase 3 sample) was performed using a custom Illumina GoldenGate Genotyping Universal-32, 1536-plex microarray.', {'entities': [(68, 76, 'platform')]}),
 (' SAGE samples were genotyped on the Illumina Human 1M array containing 1,069,796 total SNPs.', {'entities': [(36, 44, 'platform')]}),
 (' Briefly, 1529 TN breast cancer cases and 3399 country-matched controls from 10 study sites were genotyped using the Illumina 660-Quad single nucleotide polymorphism (SNP) array, CNV370 SNP array and 550-Duo SNP array ().', {'entities': [(117, 125, 'platform')]}),
 ('The design of the custom Illumina Infinium array (iCOGS) array (211 155 SNPs) and genotyping methods has been described previously ().', {'entities': [(25, 33, 'platform')]}),
 ('Expression profiles were generated for a total of 702 TN tumors (Supplementary Table S2, available at Carcinogenesis  Online) using the Illumina whole genome complementary DNA-mediated annealing, selection, extension and ligation assay (v4.0).', {'entities': [(136, 144, 'platform')]}),
 ('Genotyping was performed at the National Cancer Institute Cancer Genomics Research Laboratory by using the Illumina HumanHap500/550/610 array.', {'entities': [(107, 115, 'platform')]}),
 (' To determine whether additional SNPs in the GC  region not included on the initial Illumina HumanHap500/550/610 array may be associated with serum DBP, we used the software program IMPUTE2 () to impute additional SNPs 500 kb upstream and downstream of the GC  region.', {'entities': [(84, 92, 'platform')]}),
 ('For the discovery phase, samples were genotyped using the Illumina Human 660W-Quadv1_A Bead Array.', {'entities': [(58, 66, 'platform')]}),
 (' As imputation is sensitive to both missingness and SNP distribution, to avoid introducing bias, a set of SNPs common to the nine Illumina subsamples available was used (N=269,840).', {'entities': [(130, 138, 'platform')]}),
 ('Genotyping was performed at Cedars Sinai Medical Center using Illumina Human610 platforms for CD and HumanCNV370 platforms for UC [, ].', {'entities': [(62, 70, 'platform')]}),
 ('Genotyping in the CHS population was carried out using the Illumina 370CNV chip and genotype calls were done using Bead-Studio software, resulting in 307,655 genotyped SNPs.', {'entities': [(59, 67, 'platform')]}),
 (' In InCHIANTI, genotyping was performed with the Illumina Infinium HumanHap550 genotyping chip (chip versions 1 and 3) as previously described ().', {'entities': [(49, 57, 'platform')]}),
 (' As reported previously (), most subjects were genotyped on the Illumina Human660W-Quadv1_A (660 W) genotyping platform.', {'entities': [(64, 72, 'platform')]}),
 (' A subset of subjects who were self-reported (Northwestern) or observer reported (Vanderbilt University) to have AA was genotyped on the Illumina Human1M-Duo (1 M) genotyping platform.', {'entities': [(137, 145, 'platform')]}),
 (' As reported previously (), most subjects were genotyped on the Illumina Human660W-Quadv1_A (660 W) genotyping platform.', {'entities': [(64, 72, 'platform')]}),
 (' A subset of subjects who were self-reported (Northwestern) or observer reported (Vanderbilt University) to have AA was genotyped on the Illumina Human1M-Duo (1 M) genotyping platform.', {'entities': [(137, 145, 'platform')]}),
 (' GWAS of the JHH case population was performed using the Illumina 610K chip (24).', {'entities': [(57, 65, 'platform')]}),
 (' GWAS of the iControls population was performed using Illumina Hap300 and Hap550 Chips.', {'entities': [(54, 62, 'platform')]}),
 (' Genotype information was obtained using Illumina HumanOmni 1M arrays and standard quality control methods.', {'entities': [(41, 49, 'platform')]}),
 ('0 exon arrays, and genome-wide genotyping was performed using Illumina HumanHap550K arrays.', {'entities': [(62, 70, 'platform')]}),
 (' The GenoMEL Phase 2 samples were genotyped on the Illumina 610k array.', {'entities': [(51, 59, 'platform')]}),
 (' White blood cell count subject/visit algorithm using electronic medical records for the five eMERGE participating sites Most subjects were genotyped on the Illumina Human660 W-Quadv1_A (660 W) genotyping platform.', {'entities': [(157, 165, 'platform')]}),
 (' Samples from subjects who were self-reported (North-western) or observer-reported (Vanderbilt University) to have more recent African ancestry were genotyped on the Illumina Human1 M-Duo (1 M) genotyping platform.', {'entities': [(166, 174, 'platform')]}),
 (' If the number listed under the “N ” header was different than the total, then the difference was the number of missing records for that variable Numbers after percents are frequencies Most subjects were genotyped on the Illumina Human660 W-Quadv1_A (660 W) genotyping platform.', {'entities': [(221, 229, 'platform')]}),
 (' Samples from subjects who were self-reported (North-western) or observer-reported (Vanderbilt University) to have more recent African ancestry were genotyped on the Illumina Human1 M-Duo (1 M) genotyping platform.', {'entities': [(166, 174, 'platform')]}),
 (' Two final samples were generated: (1) A total of 422 of white (non-Hispanic) CAMP subjects and their parents were genotyped on Illumina’s Human-Hap550 Genotyping BeadChip.', {'entities': [(128, 136, 'platform')]}),
 (' (2) An additional 150 CAMP probands who did not have parental DNA were genotyped with the Illumina Infinium HD Human610-Quad BeadChip.', {'entities': [(91, 99, 'platform')]}),
 (' From these data, two separate datasets were generated: (1) 422 parent–offspring trios genotyped on Illumina’s Human-Hap550 Genotyping BeadChip, and (2) a merged HumanHap550/Human610-Quad data set composed of 572 CAMP probands.', {'entities': [(100, 108, 'platform')]}),
 (' An additional 150 CAMP probands were available who had genotyping performed with the Illumina Infinium HD Human610-Quad BeadChip.', {'entities': [(86, 94, 'platform')]}),
 (' Replicate genotyping was performed using the Illumina BeadStation 500G system ().', {'entities': [(46, 54, 'platform')]}),
 (' Genome-wide genotyping was completed in these 999 children using the Illumina HumanOmni2.5-Quad v1.', {'entities': [(70, 78, 'platform')]}),
 ('ASGC cases and controls were genotyped using the Illumina HumanHap610-Quad array.', {'entities': [(49, 57, 'platform')]}),
 (' Our total list of individuals with goiter consists of 691 individuals, of whom 217 have been genotyped using the Illumina SNP chip platform and 329 have their genotypes imputed using two-way imputation based on first- or second-degree SNP chip–genotyped relatives.', {'entities': [(114, 122, 'platform')]}),
 ('  We performed SNP genotyping of 4497 African-American samples and 3292 Caucasian samples on the Illumina 550 k chip with the remaining samples genotyped on the Human610-Quad version 1 array.', {'entities': [(97, 105, 'platform')]}),
 (' After data normalization and canonical genotype clustering according to Illumina standard protocols, we only included samples with a call rate of >98% for further analysis.', {'entities': [(73, 81, 'platform')]}),
 (' We performed SNP genotyping of 4497 African-American samples and 3292 Caucasian samples on the Illumina 550 k chip with the remaining samples genotyped on the Human610-Quad version 1 array.', {'entities': [(96, 104, 'platform')]}),
 (' After data normalization and canonical genotype clustering according to Illumina standard protocols, we only included samples with a call rate of >98% for further analysis.', {'entities': [(73, 81, 'platform')]}),
 ('0 array or Illumina Omni or 1 M platforms within each cohort using methods described previously (,).', {'entities': [(11, 19, 'platform')]}),
 (' Additional details of the ROS and MAP cohorts as well as the cognitive and pathologic phenotypes are described in prior publications (; )The Knight-ADRC and UW samples were genotyped with the Illumina 610 or the Omniexpress chip.', {'entities': [(193, 201, 'platform')]}),
 (' The ADNI samples were genotyped with the Illumina 610 chip, and the UPenn sample with the Omniexpress.', {'entities': [(42, 50, 'platform')]}),
 ('15 was used, as recommended by Illumina Technical Support, which led to the removal of 1.7% of SNPs from further analysis.', {'entities': [(31, 39, 'platform')]}),
 (' From this study, we selected 422 white, non-Hispanic participants and their parents for genotyping on the HumanHap550 v3 BeadChip (Illumina); of this group, 118 trios (consisting of a child and his or her two parents) were randomly assigned to budesonide.', {'entities': [(132, 140, 'platform')]}),
 (' In parallel, mRNA expression was quantified with Illumina HumanHT-12 Expression BeadChips.', {'entities': [(50, 58, 'platform')]}),
 ('  A GWAS of spherical equivalent using the Illumina HumanOmni2.5 chip (2.', {'entities': [(43, 51, 'platform')]}),
 (' A GWAS of spherical equivalent using the Illumina HumanOmni2.5 chip (2.', {'entities': [(42, 50, 'platform')]}),
 ('All AREDS and KORA high-quality SNPs were filtered by those present on the Illumina Omni2.5 array to produce a reduced set of genotypes for imputing to the HapMap.', {'entities': [(75, 83, 'platform')]}),
 ('A total of 186 GD1 patients confirmed to be homozygous for N370S mutation were genotyped on Illumina 650 SNP array, which contains 620,901 SNPs.', {'entities': [(92, 100, 'platform')]}),
 (' As for the melanoma risk association study, the samples were previously genotyped by the Illumina Omni 1M Quad V1-0_B SNP chip ().', {'entities': [(90, 98, 'platform')]}),
 ('Genome-wide single nucleotide polymorphism (SNP) data for approximately 300K SNPs and CNVs (from the Illumina HumanCytoSNP-350 (http://www.', {'entities': [(101, 109, 'platform')]}),
 (' Briefly, DNA from samples received were bisulfite converted and the methylation profile of the samples were evaluated using the Illumina Infinium Human DNA Methylation27 platform.', {'entities': [(129, 137, 'platform')]}),
 (' Sampling and genotyping (using the Illumina Human 660W-Quadv1_A chip) was undertaken in two rounds (see  for details).', {'entities': [(36, 44, 'platform')]}),
 ('0 chip for ARIC and the Illumina 370CNV chip for CHS.', {'entities': [(24, 32, 'platform')]}),
 (' The final SLEGEN+Illumina data set consists of 720 affected women and 2,337 controls.', {'entities': [(18, 26, 'platform')]}),
 (' ‘Out-of-study’ Illumina controls were randomized evenly to Set 1 and Set 2. Each set was analyzed separately and in a combined joint analysis.', {'entities': [(16, 24, 'platform')]}),
 (' Samples were processed according to the Illumina Infinium 2 Assay instruction manual.', {'entities': [(41, 49, 'platform')]}),
 (' Normalized bead intensity data obtained for each sample were loaded into the Illumina BeadStudio 2.0 (and 3.', {'entities': [(78, 86, 'platform')]}),
 (' Normalized bead intensity data obtained for each sample were loaded into the Illumina BeadStudio 3.1 software, which converted fluorescence intensities into SNP genotypes.', {'entities': [(78, 86, 'platform')]}),
 (' The 210 strongest associations from the Illumina 317K array (177 from the HLA region and 33 from across the remaining portion of the genome) were entered into a multiple logistic regression model for SLE using the stepwise model building method (that is, forward selection with backward elimination).', {'entities': [(41, 49, 'platform')]}),
 (' Before ‘out-of-study’ controls from Illumina were available, we used the cases from Set 1 and Set 2 and the initially available controls to identify polymorphisms for follow-up in the subsequent replication sample sets.', {'entities': [(37, 45, 'platform')]}),
 (' Samples of European ancestry or unknown ancestry were analyzed using the Illumina Human660W-Quadv1_A genotyping platform, consisting of 561,490 SNPs and 95,876 intensity-only probes.', {'entities': [(74, 82, 'platform')]}),
 (' The sample included 652 keratoconus cases from Australia (n  = 517) and Northern Ireland (n  = 135), who were genotyped in 2 Sequenom multiplexes at the Australian Genotyping Research Facility; 2,761 samples typed on Illumina HumanHap610 arrays from the Blue Mountains Eye Study were used as controls.', {'entities': [(218, 226, 'platform')]}),
 (' US keratoconus cases (n  = 222) and controls (n  = 3,324) were genotyped on Illumina HumanHap370 arrays.', {'entities': [(77, 85, 'platform')]}),
 (' Briefly, total RNA was isolated from purified monocytes using RNeasy Mini kits (Qiagen, Hilden, Germany) and hybridized to Illumina HT-12 v3 BeadChips (www.', {'entities': [(124, 132, 'platform')]}),
 (' Genotyping for the validation populations was done using TaqMan allelic discrimination assay on an ABI 7900 system (Applied Biosystems), except one (rs3850370) by SNP chip (Illumina 610k Quad, Call rate: 100%), and one (rs41997) by imputation analysis using the LD information from the 1000 Genomes Project database [by MACH, the estimated squared correlation (r _2 ) between imputed and true underlying genotypes is 1.00, indicating an excellent imputation quality] for the Harvard cohort.', {'entities': [(174, 182, 'platform')]}),
 (' Genomic DNA (gDNA) was extracted from bloodspots by using the protocol described by St Julien et al and genotyped (Illumina HumanOmni2.5 beadchip, San Diego, CA).', {'entities': [(116, 124, 'platform')]}),
 (' Nonamplified gDNA was used and the genotype calls were made by using GenomeStudio software (Illumina, 2011) after quality control procedures (Supplemental Methods).', {'entities': [(93, 101, 'platform')]}),
 (' All DNA replication samples were genotyped by using the Illumina HumanExome beadchip with custom SNP content added for the 5673 SNPs.', {'entities': [(57, 65, 'platform')]}),
 (' Nonamplified gDNA was used and genotype calls were made by using GenomeStudio software (Illumina, 2011).', {'entities': [(89, 97, 'platform')]}),
 (' Once the data from the multiple sites and different Illumina arrays were merged, there were 983,441 SNPs genotyped across the complete sample of 737 trios.', {'entities': [(53, 61, 'platform')]}),
 (' A total of 680 samples, including 16 blind duplicates and 13 HapMap controls (11 Utah residents of European ancestry, CEU and 2 Yoruban controls, YRI) were genotyped on the Illumina 1M Human Omni1-Quad array at the Center for Inherited Disease Research (http://www.', {'entities': [(174, 182, 'platform')]}),
 ('AC and MA DNA samples were genotyped using the Illumina Human1M-Duov3_B SNP array and the BeadStudio calling algorithm (version 3.1.', {'entities': [(47, 55, 'platform')]}),
 ('0) and NE DNA samples were genotyped using the Illumina Human 610 Quad v1 B SNP array and the BeadStudio calling algorithm at the Broad Institute Center for Genotyping and Analysis (CGA).', {'entities': [(47, 55, 'platform')]}),
 (' TH DNA samples were genotyped using the Illumina HumanOmni1-Quad v1–0 B SNP array at the Center for Inherited Disease Research (CIDR).', {'entities': [(41, 49, 'platform')]}),
 ('CNVision (), a pipeline specifically designed for use with Illumina microarray data, was used to predict and analyze CNVs using three algorithms with two independent approaches: GNOSIS (), PennCNV June 16, 2011 version (), and QuantiSNP version 1.1 ().', {'entities': [(59, 67, 'platform')]}),
 (' RNA samples (quality control of RNA concentration and 260/280 nm ratios using Nanodrop®) (Invitrogen, Carlsbad, California, USA) were hybridized to whole genome microaray Illumina® HumanHT-12 v4 Expression BeadChips (over 25,000 genes and 48,000 probes) in two batches.', {'entities': [(172, 180, 'platform')]}),
 (' The data were exported from Illumina® GenomeStudio and log2 transformed.', {'entities': [(29, 37, 'platform')]}),
 ('1 million SNPs using the Illumina 1M BeadChip at the Broad Institute.', {'entities': [(25, 33, 'platform')]}),
 ('Greater than 930K SNPs from the Illumina 1M BeadChip were tested for an association with PR interval, QRS duration, QTc interval, and heart rate using linear regression assuming an additive genetic model.', {'entities': [(32, 40, 'platform')]}),
 (' SARP and CSGA samples were genotyped with the Illumina HumanHap1M BeadChip.', {'entities': [(47, 55, 'platform')]}),
 (' ACRN samples were genotyped with the Illumina HumanOmniExpress700k BeadChip.', {'entities': [(38, 46, 'platform')]}),
 ('Genotyping in stage 1 was conducted using the Illumina Human1M-Duo BeadChip.', {'entities': [(46, 54, 'platform')]}),
 (' Phased haplotypes from the120 CEU and 120 YRI founders in HapMap Phase 2 were used to infer genotypes of all Phase 2 SNPs that were not available on the Illumina 1M Duo or did not pass our quality control (QC) criteria.', {'entities': [(154, 162, 'platform')]}),
 (' NCBI Build 36 (hg18) mapping was used (Illumina manifest file Immuno_BeadChip_11419691_B.', {'entities': [(40, 48, 'platform')]}),
 ('ADNI participants contributed blood samples from which DNA was extracted and were genotyped using the Illumina Human Genome 610 Quad BeadChips.', {'entities': [(102, 110, 'platform')]}),
 ('30), containing variants matched on MAF distribution, sampled without replacement from the set of typed SNPs on the Illumina 1M platform; MAF matching was done by drawing from the platform SNPs, which had been grouped into discrete MAF bins, each spanning 5% of the allele frequency spectrum.', {'entities': [(116, 124, 'platform')]}),
 (' Cases and 2,429 newly genotyped controls (pre-QC) were scanned with the Illumina 660W chip.', {'entities': [(73, 81, 'platform')]}),
 ('Genotyping was attempted for a total of 5,084 GliomaScan samples on Illumina 660W arrays at the CGF.', {'entities': [(68, 76, 'platform')]}),
 (' Genotypes were determined using Illumina chips; methods, quality control steps and imputation of untyped HapMap 2 SNPs were as previously described ().', {'entities': [(33, 41, 'platform')]}),
 (' A total of 10 015 women (mothers from the ALSPAC cohort) were genotyped using the Illumina 660 quad SNP chip which contains 557 124 SNP markers.', {'entities': [(83, 91, 'platform')]}),
 (" Genome-wide IBS distances for each pair of individuals were calculated on markers shared between the HapMap and the Illumina 660K SNP chip, and then the multidimensional scaling option in R was used to generate a two-dimensional plot based upon individuals' scores on the first two principal coordinates from this analysis.", {'entities': [(117, 125, 'platform')]}),
 ('The GWAS genotyping of the SSc cases and controls was performed as follows: the Spanish SSc cases and controls together with Dutch and German SSc cases were genotyped at the Department of Medical Genetics of the University Medical Center Utrecht (The Netherlands) using the commercial release Illumina Human CNV370K BeadChip.', {'entities': [(293, 301, 'platform')]}),
 (' Genotype data for Dutch and German controls were obtained from the Illumina Human 550KBeadChip available from a previous study.', {'entities': [(68, 76, 'platform')]}),
 (' The SSc case group from the USA was genotyped at the Boas Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, North Shore Long Island Jewish Health System using the Illumina Human 610-Quad BeadChip.', {'entities': [(196, 204, 'platform')]}),
 (' Genotyping of the TwinUK4 was done on the Illumina HumanHap650K platform.', {'entities': [(43, 51, 'platform')]}),
 (' The SAFOS samples were genotyped using the Illumina 550 HumanHap Beadchip by the Texas Biomedical Research Institute as part of the San Antonio Family Heart Study.', {'entities': [(44, 52, 'platform')]}),
 (' Controls were genotyped using an Illumina Infinium 1.2M array as part of WTCCC2, and called using the Illuminus algorithm, using genotypes that were successfully called with posterior probability >0.', {'entities': [(34, 42, 'platform')]}),
 (' These discrepancies appeared to be due to poor genotyping of these SNPs on the Illumina 610K platform.', {'entities': [(80, 88, 'platform')]}),
 (' MetaboChip SNPs were imputed in WHI-SHARE participants using genome-wide genotype data (Affymetrix 6.0 SNP array), as previously described ().', {'entities': [(89, 99, 'platform')]}),
 ('DEPICT used data from 37,427 human microarray samples captured on the Affymetrix HGU133a2.0 platform to test if genes in the 38 migraine loci are highly expressed in 209 tissues/cell types with Medical Subject Heading (MeSH) annotations.', {'entities': [(70, 80, 'platform')]}),
 ('A total of 868,158 autosomal SNPs across the entire genome were genotyped using the Affymetrix 6.0 platform for each participant.', {'entities': [(84, 94, 'platform')]}),
 (' Phenotype and Affymetrix 6.0 genotype data from MESA participants were made publicly available through the NCBI’s database of Genotypes and Phenotypes (dbGaP) and were downloaded for the current analysis.', {'entities': [(15, 25, 'platform')]}),
 (' A total of 909,622 autosomal SNPs across the entire genome were genotyped using the Affymetrix 6.0 platform for each participant.', {'entities': [(85, 95, 'platform')]}),
 (' Whole-genome gene expression profiling in the\nlung was performed on a custom Affymetrix array (GPL10379).', {'entities': [(78, 88, 'platform')]}),
 (' Genotyping was performed with the Affymetrix Genome-Wide Human SNP Array 6.0 chip containing 906,600 SNP markers.', {'entities': [(35, 45, 'platform')]}),
 (' All samples were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0_TM .', {'entities': [(38, 48, 'platform')]}),
 (' Briefly, genome-wide genotyping was performed by Affymetrix Axiom array from which 618,793 SNPs passed genotyping quality control.', {'entities': [(50, 60, 'platform')]}),
 ('A total of 868,158 autosomal SNPs across the entire genome were genotyped using the Affymetrix 6.0 platform for each participant.', {'entities': [(84, 94, 'platform')]}),
 (' Phenotype and Affymetrix 6.0 genotype data of MESA participants were made publicly available through the NCBI’s database of Genotypes and Phenotypes (dbGaP) and were downloaded for the current analysis.', {'entities': [(15, 25, 'platform')]}),
 (' A total of 909,622 autosomal SNPs across the entire genome were genotyped using the Affymetrix 6.0 platform for each participant.', {'entities': [(85, 95, 'platform')]}),
 (' Germline genotyping for the METABRIC study was also performed on the Affymetrix SNP 6.0 array, and ancestry estimation and imputation for this data set were conducted as described for TCGA.', {'entities': [(70, 80, 'platform')]}),
 (' All participants were individually genotyped with the Affymetrix human mapping SNP 6.0 assay according to the manufacturer’s recommendation.', {'entities': [(55, 65, 'platform')]}),
 ('Germline DNA samples were collected at remission and genotyped with the Affymetrix GeneChip Human Mapping 100K and 500K Array Sets.', {'entities': [(72, 82, 'platform')]}),
 ('0 chips (set 1); 8,174 unique samples, including the above 6,085 samples plus 2,089 samples from ACCORD participants who consented to genetic studies only if conducted by ACCORD investigators were genotyped at the University of North Carolina on Affymetrix Axiom Biobank1 chips (set 2).', {'entities': [(246, 256, 'platform')]}),
 (' Germline SNP genotypes (Affymetrix 6.0 arrays) were\ndownloaded through the TCGA controlled access portal (https://tcga-data.', {'entities': [(25, 35, 'platform')]}),
 (' To assess\nuntyped SNPs, we imputed genotypes present in the 1000 Genomes dataset Phase 3v5 in the\nrisk locus region (±100 kb of the lead SNP, rs1740828) for SNPs that were not genotyped by\nthe Affymetrix 6.0 platform.', {'entities': [(194, 204, 'platform')]}),
 ('Genome-wide genotyping was carried out on 3031 GeneBank subjects of European ancestry using the Affymetrix Genome-Wide Human Array 6.0 SNP chip.', {'entities': [(96, 106, 'platform')]}),
 (' WHI-SHARe and MESA participants were genotyped with the Affymetrix 6.0 chip, and imputation was performed with MaCH ().', {'entities': [(57, 67, 'platform')]}),
 (' In the replication stage II, genotyping data were extracted from our previous study using the Affymetrix Genome-Wide Human SNP Array 6.0, the quality control filtering of the genotyping data can be found elsewhere [].', {'entities': [(95, 105, 'platform')]}),
 ('0 chips (Set 1); 8,174 unique samples, including the above 6,085 samples plus 2,089 samples from ACCORD participants who consented to genetic studies only if conducted by ACCORD investigators, were genotyped at the University of North Carolina on Affymetrix Axiom Biobank1 chips (Set 2).', {'entities': [(247, 257, 'platform')]}),
 ('We investigated for evidence of association between the SNPs at each locus and tissue specific changes in gene expression using two publically available resources: (i) RNAseq and Affymetrix 6.0 SNP data for 150 TGCT patients from The Cancer Genome Atlas and (ii) normal testicular tissue data from GTEx from 157 samples.', {'entities': [(179, 189, 'platform')]}),
 (' These brain samples were confirmed to be free of neurodegenerative disorders and assayed by Affymetrix Human Exon 1.0 ST array.', {'entities': [(93, 103, 'platform')]}),
 (' Genotyping was performed at the SJCRH Hartwell Center for Bioinformatics and Biotechnology using the Affymetrix (Santa Clara, CA) Genome-Wide Human SNP Array 6.0.', {'entities': [(102, 112, 'platform')]}),
 (' Publicly available Affymetrix SNP Array 6.0 Chip data for additional 643,600 SNPs were also obtained for the same cell lines.', {'entities': [(20, 30, 'platform')]}),
 (' RNA quality was tested using an Agilent 2100 Bioanalyzer, followed by hybridization to Affymetrix U133 Plus 2.0 Gene-Chips.', {'entities': [(88, 98, 'platform')]}),
 (' Genotyping was performed on either or both of the 250 K arrays (Nsp and Sty) of the Affymetrix GeneChip Human Mapping 500 K array.', {'entities': [(85, 95, 'platform')]}),
 ('  The Chinese GWAS was originally performed on 181 sporadic cases and 346 controls of matched ancestry () using Affymetrix 500K, which assays 493\xa0840 SNPs across the genome.', {'entities': [(112, 122, 'platform')]}),
 (' We later included an additional set of 271 controls, of which 181 were genotyped by another array—Affymetrix Genome-Wide Human SNP Array 5.0 ()—which includes all the SNPs of the original 500K array but differs by inclusion of extra non-polymorphic probes for copy number analysis.', {'entities': [(99, 109, 'platform')]}),
 (' Genotyping was performed on either or both of the 250 K arrays (Nsp and Sty) of the Affymetrix GeneChip Human Mapping 500 K array.', {'entities': [(85, 95, 'platform')]}),
 (' The Chinese GWAS was originally performed on 181 sporadic cases and 346 controls of matched ancestry () using Affymetrix 500K, which assays 493\xa0840 SNPs across the genome.', {'entities': [(111, 121, 'platform')]}),
 (' We later included an additional set of 271 controls, of which 181 were genotyped by another array—Affymetrix Genome-Wide Human SNP Array 5.0 ()—which includes all the SNPs of the original 500K array but differs by inclusion of extra non-polymorphic probes for copy number analysis.', {'entities': [(99, 109, 'platform')]}),
 (' For the Chinese GWAS, only samples genotyped by the Affymetrix 500K platform were included to avoid spurious results.', {'entities': [(53, 63, 'platform')]}),
 (' In addition, as a supplementary analysis, we also imputed genotypes of SNPs not represented on the Affymetrix array using the 1000 Genomes phase 3 version 5 reference panel, mixed population (), on the University of Michigan Imputation Server (), and assessed their PM associations using the same model above (, available online).', {'entities': [(100, 110, 'platform')]}),
 ('Whole-genome gene expression profiling in 409 adjacent normal lung samples obtained from patients undergoing resection for lung cancer therapy was performed on a custom Affymetrix array (GPL10379).', {'entities': [(169, 179, 'platform')]}),
 (' The Harvard controls had been previously genotyped on the Affymetrix 6.0 platform.', {'entities': [(59, 69, 'platform')]}),
 (' In brief, before merging, an initial Affymetrix quality control check identified 35 samples that did not pass the FQC genotyping call rate of >86% on a subset of 3022 SNPs or that failed a process QC.', {'entities': [(38, 48, 'platform')]}),
 (' Genotyping was performed on Affymetrix 6.0 arrays.', {'entities': [(29, 39, 'platform')]}),
 (' Genotyping was performed on the Affymetrix 500K arrays, followed by quality control and imputation to Phase 1 1000 Genomes reference panel.', {'entities': [(33, 43, 'platform')]}),
 (' In this study, 2,981 participants of the Framingham Offspring Cohort (FOC), who had complete genotypic (Affymetrix 500K and 50K) and plasma L-arginine measurements were analysed after exclusions.', {'entities': [(105, 115, 'platform')]}),
 (' (Santa Clara, CA, USA) performed the genotyping according to manufacturer’s protocol using the Affymetrix Genome-Wide Human SNP Array 6.0.', {'entities': [(96, 106, 'platform')]}),
 (' Genotyping was done on a custom Affymetrix Axiom array (UK BiLEVE array; Santa Clara, CA) and non-genotyped variants were imputed using a combined 1000 Genomes Project Phase and UK10K Project reference panel.', {'entities': [(33, 43, 'platform')]}),
 (' CPS-II was genotyped on a custom Affymetrix Axiom array (1.3M SNPs).', {'entities': [(34, 44, 'platform')]}),
 (' WHI-SHARe and MESA participants were genotyped with the Affymetrix 6.0 chip, and imputation was performed with MaCH.', {'entities': [(57, 67, 'platform')]}),
 (' Genotyping of 89 341 saliva samples from the European (EUR) ancestry study subjects was completed using 3 Affymetrix Gene Titan systems and 3 Beckman Biomek Systems.', {'entities': [(107, 117, 'platform')]}),
 (' The Affymetrix Powertools Package, version 1.12.', {'entities': [(5, 15, 'platform')]}),
 (' The Affymetrix Axiom EUR array included 674 112 SNPs: 116 were mitochondrial, 289 were on the Y chromosome, 388 were in pseudo-autosomal regions of the X and Y chromosomes, and the remaining 660 989 SNPs were autosomal.', {'entities': [(5, 15, 'platform')]}),
 ('We used 2,206 principal components that had been derived from 77,840 Affymetrix microarrays (54,736 human, 17,081 mouse and 6,023 rat).', {'entities': [(69, 79, 'platform')]}),
 (' We subsequently used Wilcoxon-Mann-Whitney tests in the human samples from the Affymetrix U133 Plus 2.0 platform to ascertain how highly each gene was expressed in samples of a certain tissue or cell type as compared to samples in other tissues and cell types.', {'entities': [(80, 90, 'platform')]}),
 ('Genome-wide genotyping in the Framingham Offspring cohort was performed on the AffymetrixGeneChip Human Mapping 500k Array Set and the 50K Human Gene Focused Panel.', {'entities': [(79, 89, 'platform')]}),
 (' The genotyping of the KORA sample was performed with the Affymetrix Human Mapping 500k Array 2 chip set (Sty I and NSP I).', {'entities': [(58, 68, 'platform')]}),
 (' Genotyping in the GHS I and GHS II was performed using the Affymetrix Genome-Wide Human SNP Array 6.0 (http://www.', {'entities': [(60, 70, 'platform')]}),
 ('Genotyping of SNPs was performed using the Affymetrix 6.0 microarray.', {'entities': [(43, 53, 'platform')]}),
 (' () for details], 14 461 reconstituted gene sets for gene set enrichment analysis and testing 209 tissue/cell types assembled from 37 427 Affymetrix U133 Plus 2.0 Array samples for enrichment in tissue/cell type expression ().', {'entities': [(138, 148, 'platform')]}),
 (' We previously performed genotyping in the component sets of Harvard GWAS using the Affymetrix 6.0 array (, ).', {'entities': [(84, 94, 'platform')]}),
 (' We previously performed genotyping in the component sets of Harvard GWAS using the Affymetrix 6.0 array (, ).', {'entities': [(84, 94, 'platform')]}),
 (' Genotyping as part of CORECT was conducted using a custom Affymetrix genome-wide platform (the Axiom CORECT Set) with ~1.3 million SNPs and insertions and deletions (indels) on two physical genotyping chips (pegs).', {'entities': [(59, 69, 'platform')]}),
 ('In GOLDN, a total of 906,600 single nucleotide polymorphisms (SNPs) were genotyped using the Affymetrix Genome-Wide Human 6.0 array and the Birdseed calling algorithm [].', {'entities': [(93, 103, 'platform')]}),
 (' Gene expression profiles were obtained using an Affymetrix array (GEO platform GPL10379).', {'entities': [(49, 59, 'platform')]}),
 (' Gene expression profiles were obtained using an Affymetrix array (GEO platform GPL10379).', {'entities': [(49, 59, 'platform')]}),
 ('0 Array and Affymetrix Rat Genome 230 2.0 Array).', {'entities': [(12, 22, 'platform')]}),
 ('0 Array and Affymetrix Rat Genome 230 2.0 Array).', {'entities': [(12, 22, 'platform')]}),
 ('On the basis of the genome-wide Affymetrix 6.0 SNP genotype data, we used Primus_,  to select 626 individuals from the discovery sample using a kinship threshold (0.', {'entities': [(32, 42, 'platform')]}),
 (' Affymetrix Probe 2724308 was used to represent the KLB  overall transcript levels.', {'entities': [(1, 11, 'platform')]}),
 (' In the Chinese GWAS (SBCGS), samples were scanned primarily using Affymetrix Genome-Wide Human SNP Array 6.0, and the initial 300 samples were scanned using the Affymetric GeneChip Mapping 500K Array Set.', {'entities': [(67, 77, 'platform')]}),
 (' In the present study, only data from Affymetrix SNP Array 6.0 were used to perform imputation.', {'entities': [(38, 48, 'platform')]}),
 (' For the Korean GWAS (SeBCS1), Affymetrix Genome-Wide Human SNP Array 6.0 was used.', {'entities': [(31, 41, 'platform')]}),
 (' SNP data genotyped using the Affymetrix SNP 6.0 array were also retrieved.', {'entities': [(30, 40, 'platform')]}),
 (' Genotype data using the Affymetrix SNP 6.0 array were downloaded from EBI (EGAD00010000164, see URLs).', {'entities': [(25, 35, 'platform')]}),
 ('01 (for Affymetrix data, we kept all variants with a MAF\u2009\u2009≥\u20090.05); SNP missingness\u2009<\u20090.', {'entities': [(8, 18, 'platform')]}),
 ('All sample processing, DNA isolation and quantitation, pooling of DNA specimens and hybridization to the Affymetrix SNP Array 6.0, was performed in the Human Genomics and Proteomics Core Laboratory of the University of Pittsburgh (www.', {'entities': [(105, 115, 'platform')]}),
 (' \n Three independent pools were created, each containing equimolar concentrations of all samples Each pool was hybridized to three Affymetrix SNP Array 6.0 chips Relative allele frequencies were derived Forty samples were randomly selected from the R1 cohort and A genome wide scan on R2 samples was performed using the steps 1–4 \nAfter results of the pooled GWAS were available, individual genotyping of 18 recipient and 3 donor SNPs was performed.', {'entities': [(131, 141, 'platform')]}),
 (' As described above, DNA samples were divided into three pools each for recipients and donors and tested in triplicate using the Affymetrix Genome-wide SNP Array 6.0.', {'entities': [(129, 139, 'platform')]}),
 ('A total of 3030 JHS participants were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0.', {'entities': [(58, 68, 'platform')]}),
 ('The cohort was genotyped at the Broad Institute using Affymetrix Genome-Wide Human SNP array 6.0 according to the manufacturer’s recommendations.', {'entities': [(54, 64, 'platform')]}),
 ('0 (Affymetrix, Santa Clara CA) assays were performed according to the manufacturer’s instructions using GeneChip Fluidics 450 Stations and a GeneChip 3000 7G Scanner.', {'entities': [(3, 13, 'platform')]}),
 (' Microarray quality control parameters and genotype calls were generated with Affymetrix Genotyping Console v4.1 software.', {'entities': [(78, 88, 'platform')]}),
 ('We genotyped (Affymetrix SNP 6.0) a longitudinal cohort of 329 women with a history of PTB at 37 weeks of gestational age.', {'entities': [(14, 24, 'platform')]}),
 (' Gene expression of HapMap cells measured by the Affymetrix GeneChip Human Exon 1.0 ST Array was downloaded from the website (http://www.', {'entities': [(49, 59, 'platform')]}),
 (' After filtering out SNPs with a call rate <95% (SNP call rate is the percentage of patients who have a confident genotype call for each SNP according to Affymetrix quality control criteria) and minor allele frequency <1%; the remaining SNPs (484,623 typed SNPs and 1,091,393 imputed SNPs) were assessed in a GWAS for their association with vincristine-induced neuropathy, in St.', {'entities': [(154, 164, 'platform')]}),
 ('GWAS samples were genotyped using the Affymetrix GeneChip_®  Human Mapping 500 K array set including a total of 500 568 SNPs (Santa Clara, California).', {'entities': [(38, 48, 'platform')]}),
 (' GWAS genotyping was\nperformed using the Affymetrix (Santa Clara, CA) genome-wide human SNP Array 6.0\nincluding 906,600 SNPs.', {'entities': [(41, 51, 'platform')]}),
 (' In brief, the UKBEC consists of 134 neuropathologically normal donors from the MRC Sudden Death Brain Bank in Edinburgh and Sun Health Research Institute; expression was profiled on the Affymetrix Exon 1.0 ST array.', {'entities': [(187, 197, 'platform')]}),
 (' The Hutterites were genotyped using the Affymetrix GeneChip® 500k or 6.0 Mapping Array.', {'entities': [(41, 51, 'platform')]}),
 ('FHS participants were genotyped with the Affymetrix Human Mapping 500K Array Set and the 50K Human Gene Focused Panel.', {'entities': [(41, 51, 'platform')]}),
 (' SHIP participants were genotyped with the Affymetrix Human SNP Array 6.0 using the Birdseed2 clustering algorithm.', {'entities': [(43, 53, 'platform')]}),
 ('The RISC and Stanford samples were genotyped using the Affymetrix 6.0 microarray\nplatform.', {'entities': [(55, 65, 'platform')]}),
 ('1 percent (892 ARIC-JHS overlap and 2,136 JHS-specific) gave consent for genetic analyses and thus were genotyped separately in the CARe consortium using Affymetrix 6.0 platform (See ).', {'entities': [(154, 164, 'platform')]}),
 (' All SNPs for the replication in African-Americans were present on the Affymetrix 6.0 SNP array used to genotype the CARe African-American sample, and were thus directly genotyped rather than imputed.', {'entities': [(71, 81, 'platform')]}),
 (' Genotyping was carried out separately for the EA and AA samples using the Affymetrix Genome-Wide Human SNP Array 6.0.', {'entities': [(75, 85, 'platform')]}),
 (' Allele calling was performed using the BirdSeed algorithm Affymetrix Power Tools version apt-1.8.', {'entities': [(59, 69, 'platform')]}),
 (' Genotyping was carried out separately for the EA and AA samples using the Affymetrix Genome-Wide Human SNP Array 6.0.', {'entities': [(75, 85, 'platform')]}),
 (' Allele calling was performed using the BirdSeed algorithm Affymetrix Power Tools version apt-1.8.', {'entities': [(59, 69, 'platform')]}),
 (' For the initial GWAS sample, genotyping with the Affymetrix Genome-Wide Human SNP Array 6.0 was performed using the standard protocol recommended by the manufacturer.', {'entities': [(50, 60, 'platform')]}),
 (' Fluorescence intensities were quantified using an Affymetrix array scanner 3000 7G.', {'entities': [(51, 61, 'platform')]}),
 (' For the replication study sample, genotyping of SNPs was performed with the same Affymetrix Genome-Wide Human SNP Array 6.0 using the standard protocol.', {'entities': [(82, 92, 'platform')]}),
 (' Total IgE levels were measured as described in GALA II, and genotyping was performed on the Affymetrix 6.0 GeneChip.', {'entities': [(93, 103, 'platform')]}),
 (' Total IgE levels were measured as described in GALA II, and genotyping was performed on the Affymetrix 6.0 GeneChip.', {'entities': [(93, 103, 'platform')]}),
 (' Affymetrix genotyping was available for 94% of patients with asparaginase hypersensitivity data (supplemental Table 1).', {'entities': [(1, 11, 'platform')]}),
 (' mRNA expression was assayed using the Affymetrix GeneChip Human Gene 1.0 ST microarray.', {'entities': [(39, 49, 'platform')]}),
 ('1% Tween20), in turn, on an Affymetrix Fluidics Station FS450. Then they were stained with the Streptavidin Phycoerythrin (SAPE, 10 µg/mL) and the signals were amplified with Anti-streptavidin antibody.', {'entities': [(28, 38, 'platform')]}),
 (' The stained arrays were scanned with an Affymetrix GeneChip® 3000 7G scanner at 0.7 urn solution and generated relevant signal images.', {'entities': [(41, 51, 'platform')]}),
 ('1% Tween20), in turn, on an Affymetrix Fluidics Station FS450. Then they were stained with the Streptavidin Phycoerythrin (SAPE, 10 µg/mL) and the signals were amplified with Anti-streptavidin antibody.', {'entities': [(28, 38, 'platform')]}),
 (' The stained arrays were scanned with an Affymetrix GeneChip® 3000 7G scanner at 0.7 urn solution and generated relevant signal images.', {'entities': [(41, 51, 'platform')]}),
 (' Whole genome genotyping performed with the Affymetrix 6.0 platform and genotype calling was performed with Birdseed calling algorithm.', {'entities': [(44, 54, 'platform')]}),
 (' Whole genome genotyping performed with the Affymetrix 6.0 platform and genotype calling was performed with Birdseed calling algorithm.', {'entities': [(44, 54, 'platform')]}),
 (' Whole genome genotyping was performed by the Affymetrix 500K platform and genotype calling was performed with Birdseed calling algorithm.', {'entities': [(46, 56, 'platform')]}),
 (' Whole genome genotyping performed with the Affymetrix 6.0 platform and genotype calling was performed with Birdseed calling algorithm.', {'entities': [(44, 54, 'platform')]}),
 (' Whole genome genotyping performed with the Affymetrix 6.0 platform and genotype calling was performed with Birdseed calling algorithm.', {'entities': [(44, 54, 'platform')]}),
 (' Whole genome genotyping was performed by the Affymetrix 500K platform and genotype calling was performed with Birdseed calling algorithm.', {'entities': [(46, 56, 'platform')]}),
 (' DEPICT also facilitated tissue and cell type enrichment analysis by testing whether the genes in associated regions were highly expressed in any of 209 MeSH annotations for 37,427 microarrays on the Affymetrix U133 Plus 2.0 Array platform.', {'entities': [(200, 210, 'platform')]}),
 (' Genotype calling was done with the Affymetrix PowerTools (APT) software package, using the AxiomGT1/brlmm-p algorithm and the manufacturer recommended calling pipeline.', {'entities': [(36, 46, 'platform')]}),
 (' In brief, a total of 906,600 SNPs were genotyped on the Affymetrix Genome-Wide Human SNP Array 6.0 using the Birdseed calling algorithm [].', {'entities': [(57, 67, 'platform')]}),
 (' In brief, a total of 906,600 SNPs were genotyped on the Affymetrix Genome-Wide Human SNP Array 6.0 using the Birdseed calling algorithm [].', {'entities': [(57, 67, 'platform')]}),
 (' The replication study described here was performed in 843 Old Order Amish participants (of a total of 868 HAPI Heart participants) who underwent a high fat feeding intervention and were successfully genotyped using the Affymetrix GeneChip_®  Human Mapping 500K Array Set.', {'entities': [(220, 230, 'platform')]}),
 ('  HAPI Heart Study participants were genotyped using the Affymetrix GeneChip_®  Human Mapping 500K Array Set which consisted of 500,568 SNP genotyping calls on each participant using the BRLMM genotype-calling algorithm.', {'entities': [(57, 67, 'platform')]}),
 (' The replication study described here was performed in 843 Old Order Amish participants (of a total of 868 HAPI Heart participants) who underwent a high fat feeding intervention and were successfully genotyped using the Affymetrix GeneChip_®  Human Mapping 500K Array Set.', {'entities': [(220, 230, 'platform')]}),
 (' HAPI Heart Study participants were genotyped using the Affymetrix GeneChip_®  Human Mapping 500K Array Set which consisted of 500,568 SNP genotyping calls on each participant using the BRLMM genotype-calling algorithm.', {'entities': [(56, 66, 'platform')]}),
 ('1 and Affymetrix GeneChip Human Mapping Array 6.0.', {'entities': [(6, 16, 'platform')]}),
 ('The initial sample was genotyped at the Broad Institute as part of the as part of the Genetic Association Information Network (GAIN) using the Affymetrix 6.0 (1 M SNP) array.', {'entities': [(143, 153, 'platform')]}),
 ('DNA was genotyped using the Affymetrix® Genome-Wide Human SNP Array 6.0.', {'entities': [(28, 38, 'platform')]}),
 ('Cases were genotyped using the Affymetrix 6.0 array.', {'entities': [(31, 41, 'platform')]}),
 (' We analyzed each of the two probes for FOPNL  on the Affymetrix U133 array separately and also considered the average of the two probes as a predictor of overall survival in the proportional hazards model.', {'entities': [(54, 64, 'platform')]}),
 (' Affymetrix HG-U133+2 arrays were used to quantitate global gene expression levels.', {'entities': [(1, 11, 'platform')]}),
 ('  We tested our predictive model in an independent training study, for which Affymetrix Gene 1.1 ST microarray data are publicly available (GSE53598), consisting of 18 overweight to obese normoglycaemic middle-aged men who underwent 12 weeks of mixed exercise training (2 days/week aerobic, 1 day/week resistance training).', {'entities': [(77, 87, 'platform')]}),
 (' We tested our predictive model in an independent training study, for which Affymetrix Gene 1.1 ST microarray data are publicly available (GSE53598), consisting of 18 overweight to obese normoglycaemic middle-aged men who underwent 12 weeks of mixed exercise training (2 days/week aerobic, 1 day/week resistance training).', {'entities': [(76, 86, 'platform')]}),
 (' All 92 lesional samples and all but two of the 82 normal samples were genotyped on the Affymetrix Axiom Biobank Plus Array, which contains a GWAS backbone panel of 260,000 SNPs in addition to exome and custom content.', {'entities': [(88, 98, 'platform')]}),
 ('A total of 5543 subjects (2383 lung cancer cases and 3160 controls) were originally genotyped using Affymetrix Genome-Wide Human SNP Array 6.0 chips containing 906 703 SNPs, followed by a systematic quality control procedure before association analysis, as described elsewhere ().', {'entities': [(100, 110, 'platform')]}),
 ('In the ARIC study, autosomal single-nucleotide polymorphisms (SNPs) were genotyped on the Affymetrix 6.0 chip and were imputed to ≈ 2.', {'entities': [(90, 100, 'platform')]}),
 (' The Stage 1 genome scan was performed using an Affymetrix Genome-Wide Human SNP Array 5.0.', {'entities': [(48, 58, 'platform')]}),
 (' Gene expression analyses were performed on data collected using Nanostring and a compendium of publicly available Affymetrix U133 Plus 2.0 microarrays.', {'entities': [(115, 125, 'platform')]}),
 ('To examine for a relationship between SNP genotype and mRNA expression we made use of Tumor Cancer Genome Atlas (TCGA) RNA-seq expression and Affymetrix 6.0 SNP data (dbGaP accession number: phs000178.', {'entities': [(142, 152, 'platform')]}),
 (' For the coronary heart disease and type 2 diabetes GWASs of the discovery set, we performed genotyping using the Affymetrix 6.0 array.', {'entities': [(114, 124, 'platform')]}),
 (' For the coronary heart disease and type 2 diabetes GWASs of the discovery set, we performed genotyping using the Affymetrix 6.0 array.', {'entities': [(114, 124, 'platform')]}),
 (' The rest, and about 54% of individuals typed with single SNP genotyping, were genotyped with the Affymetrix SNP 6.0 array, and either direct or imputed genotypes were available for all the 19 variants.', {'entities': [(98, 108, 'platform')]}),
 ('A total of 10 004 samples were genotyped using Affymetrix Genome-Wide Human Single Nucleotide Polymorphism (SNP) 5.0 arrays and processed with Bayesian Robust Linear Modelling using the Mahalanobis Distance genotyping algorithm.', {'entities': [(47, 57, 'platform')]}),
 (' All ARIC samples genotyped on the Affymetrix SNP array 6.0 were controls, whereas all cases and the remaining controls were genotyped on the Axiom array.', {'entities': [(35, 45, 'platform')]}),
 (' Gene expression profiling was performed using an Affymetrix custom array (GEO platform GPL10379) testing 51,627 non-control probe sets and normalized using RMA.', {'entities': [(50, 60, 'platform')]}),
 (' After applying previously implemented quality control procedures (), we performed GWA analyses of 729,454 single nucleotide polymorphism (SNP) markers using 1001 European American bipolar cases and 1034 mentally healthy European American controls, genotyped on the Affymetrix Genome-Wide Human SNP Array 6.0.', {'entities': [(266, 276, 'platform')]}),
 ('0 (Affymetrix) derived cell intensity files (CEL) were processed in R 2.1.', {'entities': [(3, 13, 'platform')]}),
 ('0 (Affymetrix) derived cell intensity files (CEL) were processed in R 2.1.', {'entities': [(3, 13, 'platform')]}),
 ('Individuals in the WHI-SHARe cohort were genotyped on the Affymetrix 6.0 array.', {'entities': [(58, 68, 'platform')]}),
 ('; and set III, samples genotyped using Affymetrix 5.0 as described by Graham et al.', {'entities': [(39, 49, 'platform')]}),
 (' The BRASS RA samples have been used in our previous 100K GWAS, but here are presented for the first time genotyped with the Affymetrix 6.0 array.', {'entities': [(125, 135, 'platform')]}),
 ('The BRASS GWAS collection was genotyped on the Affymetrix Genechip 6.0 platform at the Broad Institute (Boston, USA).', {'entities': [(47, 57, 'platform')]}),
 (' For the WTCCC collection, genotyped on the older Affymetrix 500K platform, we implemented more stringent QC (>1% missing data, MAF<1%, <10_−5 ).', {'entities': [(50, 60, 'platform')]}),
 ('Hutterite individuals were genotyped with the Affymetrix GeneChip 500k, Genome-Wide SNP 5.0, or Genome-Wide SNP 6.', {'entities': [(46, 56, 'platform')]}),
 (' Genotyping was performed via hybridization to a custom Affymetrix genome-wide platform (the Axiom® CORECT Set) containing ~1.3 million SNPs and indels spread across two physical genotyping chips (pegs).', {'entities': [(56, 66, 'platform')]}),
 (' All DNA samples from the 10,004 participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 5.0.', {'entities': [(70, 80, 'platform')]}),
 (' All DNA samples from the 10,004 participants were genotyped with the Affymetrix Genome-Wide Human SNP Array 5.0.', {'entities': [(70, 80, 'platform')]}),
 ('Genome-wide SNP genotyping was performed by using the Affymetrix Human SNP Array 6.0 for ALL cases in the discovery GWAS, those in the COG P9905, P9904, and AALL0232 cohorts, and for all non-ALL controls (dbGaP MESA, ALIVE, GAIN, and GALA).', {'entities': [(54, 64, 'platform')]}),
 (' Genotype calls (coded as 0, 1, and 2 for AA, AB, and BB genotypes) were determined by the Birdseed v2 (Affymetrix SNP 6.0) algorithm.', {'entities': [(104, 114, 'platform')]}),
 (' For the ALL cases in the COG P9906 trial, genome-wide SNP genotyping was performed by using Affymetrix Human SNP Array 500K, and GATA3  SNPs were genotyped by polymerase chain reaction and Sanger sequencing, as described previously.', {'entities': [(93, 103, 'platform')]}),
 (' GATA3  expression was quantified in 237 ALL blasts in 237 AYA cases, using Affymetrix U133A array.', {'entities': [(76, 86, 'platform')]}),
 ('  Genome-wide genotyping used the Affymetrix Genome-Wide Human SNP Array 6.0 (CA, USA) at the Ramaciotti Centre, UNSW, Sydney, Australia, following the recommended protocol.', {'entities': [(34, 44, 'platform')]}),
 (' Genome-wide genotyping used the Affymetrix Genome-Wide Human SNP Array 6.0 (CA, USA) at the Ramaciotti Centre, UNSW, Sydney, Australia, following the recommended protocol.', {'entities': [(33, 43, 'platform')]}),
 ('Both cases and controls were genotyped using the Affymetrix6.0 array at CapitalBio Ltd.', {'entities': [(49, 59, 'platform')]}),
 (' The Affymetrix 6.0 array included 906,600 SNP probes and 946,000 CNV probes.', {'entities': [(5, 15, 'platform')]}),
 ('In KORA F4 genotyping was done using the Affymetrix 6.0 GeneChip array.', {'entities': [(41, 51, 'platform')]}),
 ('Genotyping was performed with the use of the Affymetrix SNP 6.0 Platform in the discovery cohort and the Sequenom MassARRAY platform in the replication cohort (see the ).', {'entities': [(45, 55, 'platform')]}),
 ('The genome-wide scan was performed using the Affymetrix Genome-Wide Human SNP Array 6.0.', {'entities': [(45, 55, 'platform')]}),
 (' Genotyping was performed using the Affymetrix Gene Chip Human Mapping 500K Array Set.', {'entities': [(36, 46, 'platform')]}),
 (' For the 56 SNPs with Sequenom genotyping rates greater than 90%, concordance with the Affymetrix data was 99.7% (based on 187,960 genotypes).', {'entities': [(87, 97, 'platform')]}),
 (' Genotypes from the Affymetrix 500K mapping array were called using Chiamo ().', {'entities': [(20, 30, 'platform')]}),
 ('SNP genotyping of the CLHNS mothers was performed with the Affymetrix Genomewide Human SNP Array 5.0 at the Vanderbilt Microarray Shared Resource at Vanderbilt University Medical Center, Nashville, TN, using the standard protocol recommended by the manufacturer.', {'entities': [(59, 69, 'platform')]}),
 (' Global gene expression in lymphoblastoid cell lines was measured using Affymetrix HG-U133 Plus 2.0 chips.', {'entities': [(72, 82, 'platform')]}),
 (' To evaluate the performance of the imputation, we randomly masked 5% of the markers (n =1,046) directly genotyped on chromosome 12 and compared the imputed genotypes with the Affymetrix genome-wide Human SNP array 5.0 genotype calls.', {'entities': [(176, 186, 'platform')]}),
 ('9 and the concordance rate observed between the Affymetrix 5.0 genotypes and the imputed genotypes was 99.', {'entities': [(48, 58, 'platform')]}),
 (' In an independent analysis, we masked 100 markers on chromosomes 4, 9, 16 and 20 from the inference files used for imputation and compared the imputed genotypes with the original genotypes obtained with the Affymetrix 5.0 microchip.', {'entities': [(208, 218, 'platform')]}),
 (' Genotyping of the KORA F4 population was carried out using the Affymetrix GeneChip array 6.0.', {'entities': [(64, 74, 'platform')]}),
 (' Genotyping of the KORA F4 population was carried out using the Affymetrix GeneChip array 6.0.', {'entities': [(64, 74, 'platform')]}),
 (' Genotyping of the KORA F4 population was carried out using the Affymetrix GeneChip array 6.0.', {'entities': [(64, 74, 'platform')]}),
 (' As a sampling dataset, we chose the 655,658 SNP from the Affymetrix 6.0 array, which have been tested in the KORA part of this study.', {'entities': [(58, 68, 'platform')]}),
 (' As a sampling dataset, we chose the 655,658 SNP from the Affymetrix 6.0 array, which have been tested in the KORA part of this study.', {'entities': [(58, 68, 'platform')]}),
 (' Briefly, samples were genotyped using the Affymetrix Genome-Wide Human 6.0 array (Santa Clara, CA).', {'entities': [(43, 53, 'platform')]}),
 ('SNP genotyping was performed on population-optimized Affymetrix Axiom Genome-Wide CEU 1 array plates following the standard manufacturer’s protocol.', {'entities': [(53, 63, 'platform')]}),
 ('We genotyped 95 HapMap individuals on Affymetrix Axiom Genome-Wide CEU 1 arrays using the same process as described above.', {'entities': [(38, 48, 'platform')]}),
 (' Furthermore, 15 samples that were previously genotyped on Affymetrix Axiom Genome-Wide CEU 1 arrays were used as control samples: the genotypes obtained by TaqMan assays were perfectly concordant with those generated with Axiom array technology.', {'entities': [(59, 69, 'platform')]}),
 (' Genotyping of the STAR*D sample was performed at Affymetrix (500K) or at the University of California, San Francisco (5.0), as described ().', {'entities': [(50, 60, 'platform')]}),
 (' The study samples were genotyped on the Affymetrix 500 K chip and SNP calling was done as described by De Wit et al .', {'entities': [(41, 51, 'platform')]}),
 ('  The Tufts/MGH and MIGen samples were genotyped at the Broad Institute and National Center for Research Resources (NCRR) Center for Genotyping and Analysis using the Affymetrix SNP 6.0 GeneChip (AFFY 6.', {'entities': [(167, 177, 'platform')]}),
 ('  Shared controls from the GAIN study obtained from dbGaP were also genotyped by using the Affymetrix SNP 6.0 GeneChip.', {'entities': [(91, 101, 'platform')]}),
 (' The Tufts/MGH and MIGen samples were genotyped at the Broad Institute and National Center for Research Resources (NCRR) Center for Genotyping and Analysis using the Affymetrix SNP 6.0 GeneChip (AFFY 6.', {'entities': [(166, 176, 'platform')]}),
 ('  Shared controls from the GAIN study obtained from dbGaP were also genotyped by using the Affymetrix SNP 6.0 GeneChip.', {'entities': [(91, 101, 'platform')]}),
 (' SNP genotyping and imputation in SMHS (n  = 230) were carried out using Affymetrix 6.0 and MACH, respectively.', {'entities': [(73, 83, 'platform')]}),
 (' Genotyping was performed using the Affymetrix GeneChip Human Mapping 500K Array Set by the Genetic Analysis Platform at the Broad Institute of Harvard and Massachusetts Institute of Technology.', {'entities': [(36, 46, 'platform')]}),
 ('There were 500,568 SNPs on the Affymetrix 500K chips and 164,871 on the\nPerlegen custom chip (665,439 SNPs in total).', {'entities': [(72, 80, 'platform')]}),
 ('2% of the Affymetrix 500K and\n33.9% of the Perlegen 164K SNPs).', {'entities': [(43, 51, 'platform')]}),
 (' Of\nthe controls used here, 277 individuals were independently genotyped using the\nAffymetrix 500K “A” chips at the MIT/Harvard Broad Institute by\nDr.', {'entities': [(83, 93, 'platform')]}),
 ('All subjects were genotyped in two sample sets for the Affymetrix SNP Array 6.0.', {'entities': [(55, 65, 'platform')]}),
 ('For BAS in the discovery stage, a total of 509 cases of MI and 1,034\ncontrols were genotyped with the Affymetrix GeneChip_®  Human\nMapping 500K Array Set, including 500,568 SNPs.', {'entities': [(102, 112, 'platform')]}),
 (' Gene expression experiment was a part of an ongoing project, conducted with Affymetrix Human Exon 1.0 ST Array following the manufacturer protocols.', {'entities': [(77, 87, 'platform')]}),
 (' In the ARIC, the Affymetrix SNP 6.0 platform was used for genotyping and MACH v1.', {'entities': [(18, 28, 'platform')]}),
 (' Genotyping was completed with TaqMan assays (ERICH Study) or Affymetrix 6.0 (GERFHS III and CCC-GCC).', {'entities': [(62, 72, 'platform')]}),
 ('We used the Affymetrix 100 and 500K mapping arrays sets.', {'entities': [(12, 22, 'platform')]}),
 (' Approximately half of the STAR*D samples were genotyped with the same 500K array and the second half with the Affymetrix Human Single Nucleotide Polymorphism (SNP) Array 5.0.', {'entities': [(111, 121, 'platform')]}),
 (' Approximately half of the STAR*D samples were genotyped with the same 500K array and the second half with the Affymetrix Human Single Nucleotide Polymorphism (SNP) Array 5.0.', {'entities': [(111, 121, 'platform')]}),
 (' Genotyping was performed using the Affymetrix 500K chip.', {'entities': [(36, 46, 'platform')]}),
 (' Means (and standard deviations) for all variables used in the analysis These samples were made available by the Framingham SHARe resource, which contains genotypes for all respondents using the Affymetrix 5.0 genotyping platform.', {'entities': [(195, 205, 'platform')]}),
 (' In Stage 1, genotyping was performed using Affymetrix Genome-Wide Human SNP Array 6.0 (Affy 6.', {'entities': [(44, 54, 'platform')]}),
 ('MSKCC samples were genotyped on early-access Affymetrix 500K (EAv3) SNP arrays as described previously ().', {'entities': [(45, 55, 'platform')]}),
 (' BCFR samples were genotyped on commercially available Affymetrix 500K SNP arrays according to manufacturer instructions.', {'entities': [(55, 65, 'platform')]}),
 (' Total RNA from the middle temporal cortex (Brodmann areas 20 and 21) from 86 subjects was isolated and randomly hybridized to Affymetrix Human Exon 1.0 ST arrays, and quality control analysis was performed using standard methods.', {'entities': [(127, 137, 'platform')]}),
 (' Expression profiling was conducted in up to ten separate brain regions for each individual brain using the Affymetrix GeneChip Human Exon 1.0 ST array.', {'entities': [(108, 118, 'platform')]}),
 ('  Genome-wide genotyping of SNPs was performed on the Affymetrix genome-wide human array 6.0 chip.', {'entities': [(54, 64, 'platform')]}),
 (' Genome-wide genotyping of SNPs was performed on the Affymetrix genome-wide human array 6.0 chip.', {'entities': [(53, 63, 'platform')]}),
 ('2M Duo chip and the Affymetrix Genome Wide Human SNP array 6.0.', {'entities': [(20, 30, 'platform')]}),
 ('MS subjects recruited through the IMSGC were genotyped on the Affymetrix platform using the GeneChip Human Mapping 500K Array set.', {'entities': [(62, 72, 'platform')]}),
 (' The BWH MS subjects were genotyped on the Affymetrix Genome-wide Human SNP Array 6.0 (GeneChip 6.', {'entities': [(43, 53, 'platform')]}),
 ('The genotyping was supported by the National Institute of Health Gene Environment Association Studies (GENEVA) project () and used the Affymetrix 6.0 platform.', {'entities': [(135, 145, 'platform')]}),
 (' DNA from ROS and MAP subjects was extracted from whole blood, lymphocytes or frozen postmortem brain tissue and genotyped on the Affymetrix Genechip 6.0 platform, as previously described ().', {'entities': [(130, 140, 'platform')]}),
 (' First-stage discovery cohort samples were genotyped using the Affymetrix version 6.0 SNP platform (Santa Clara, California).', {'entities': [(63, 73, 'platform')]}),
 (' Genomewide Affymetrix SNP 6.0 Array genotype data were available for the SHARP and CARE Network samples.', {'entities': [(12, 22, 'platform')]}),
 (' Genotyping was performed using the Affymetrix Genome-Wide Human SNP Array 6.0.', {'entities': [(36, 46, 'platform')]}),
 (' Genotyping was performed using the Affymetrix Genome-Wide Human SNP Array 6.0.', {'entities': [(36, 46, 'platform')]}),
 (' A cohort of 8,515 self-identified AA and 3,642 self-identified HA participants from WHI, who had consented to genetic research, were selected for WHI SHARe (n = 12,157) and genotyped on the Affymetrix 6.0 array.', {'entities': [(191, 201, 'platform')]}),
 (' A cohort of 8,515 self-identified AA and 3,642 self-identified HA participants from WHI, who had consented to genetic research, were selected for WHI SHARe (n = 12,157) and genotyped on the Affymetrix 6.0 array.', {'entities': [(191, 201, 'platform')]}),
 (' DNA samples were genotyped using Affymetrix 250K StyI  arrays.', {'entities': [(34, 44, 'platform')]}),
 (' We scanned arrays with the GeneChip Scanner 3000, and used the Affymetrix Genotyping Tools Version 2.0 to ascertain genotypes.', {'entities': [(64, 74, 'platform')]}),
 ('For principal component analysis we used genome-wide data from the 217 MPN cases and from 3,000 controls from the Wellcome Trust Case Control consortium, which were genotyped with the Affymetrix GeneChip 500k Mapping Array Set, of which the 250 K Sty chip is a subset.', {'entities': [(184, 194, 'platform')]}),
 (' SNP genotyping was performed with Affymetrix Genome-Wide Human SNP Array 6.0 following standard protocol of the manufacturer.', {'entities': [(35, 45, 'platform')]}),
 (' Fluorescence intensities were quantified using an Affymetrix array scanner 3000 7G.', {'entities': [(51, 61, 'platform')]}),
 ('  For the CAU-2 sample, genotyping of SNPs of interest was performed with the Affymetrix Mapping 250 k Nsp and 250 k Sty arrays in Vanderbilt Microarray Shared Resources (VMSR) (http://array.', {'entities': [(78, 88, 'platform')]}),
 (' For the CAU-3 sample from FHS, SNPs of interest were genotyped using the Affymetrix Mapping 500 k arrays.', {'entities': [(74, 84, 'platform')]}),
 (' For the CHN sample, SNPs genotyping was performed with Affymetrix Genome-Wide Human SNP Array 6.0 using standard protocol.', {'entities': [(56, 66, 'platform')]}),
 (' SNP genotyping was performed with Affymetrix Genome-Wide Human SNP Array 6.0 following standard protocol of the manufacturer.', {'entities': [(35, 45, 'platform')]}),
 (' Fluorescence intensities were quantified using an Affymetrix array scanner 3000 7G.', {'entities': [(51, 61, 'platform')]}),
 (' For the CAU-2 sample, genotyping of SNPs of interest was performed with the Affymetrix Mapping 250 k Nsp and 250 k Sty arrays in Vanderbilt Microarray Shared Resources (VMSR) (http://array.', {'entities': [(77, 87, 'platform')]}),
 (' For the CAU-3 sample from FHS, SNPs of interest were genotyped using the Affymetrix Mapping 500 k arrays.', {'entities': [(74, 84, 'platform')]}),
 (' For the CHN sample, SNPs genotyping was performed with Affymetrix Genome-Wide Human SNP Array 6.0 using standard protocol.', {'entities': [(56, 66, 'platform')]}),
 (' The genotype data, derived from the Affymetrix Genome Wide 6.0 SNP chip, were the genotype calls produced by the Birdseed algorithm from the probesets’ intensity values normalized by the Invariant Set Median-Polish algorithm (https://tcga-data.', {'entities': [(37, 47, 'platform')]}),
 (' Non-ALL control subjects in both the GWAS and replication series were genotyped using Affymetrix Human SNP Array 6.0.', {'entities': [(87, 97, 'platform')]}),
 ('4%) genotyped with the Affymetrix 5.0 chip.', {'entities': [(23, 33, 'platform')]}),
 (' The SOPHIA study genotyped 177 PE cases and 116 normotensive controls using the Affymetrix Genome-Wide Human SNP Array 6.0 ().', {'entities': [(81, 91, 'platform')]}),
 ('Genotyping for the METH-dependence GWAS was performed using the Affymetrix Genome-Wide Human SNP Array 5.0 or 6.', {'entities': [(64, 74, 'platform')]}),
 (' The healthy controls were genotyped using the Affymetrix 6.0 chip.', {'entities': [(47, 57, 'platform')]}),
 (' The genotyping platform for the Japanese SCZ Study was Affymetrix 5.0, and SNPs were evaluated using the same procedures used in our previous study ().', {'entities': [(56, 66, 'platform')]}),
 (' For the ROS/MAP replication cohort, DNA was extracted from blood samples or frozen postmortem brain tissue and genotyped on the Affymetrix Genechip 6.0 platform as previously described.', {'entities': [(129, 139, 'platform')]}),
 (' Genotypes were called for 1,890 samples passing quality control (QC) using both the Affymetrix supported Birdseed v2 [] calling algorithm as well as the corrected robust linear model with maximum likelihood classification (CRLMM) [] and only calls in complete agreement between the two algorithms were used in analyses.', {'entities': [(85, 95, 'platform')]}),
 (' Copy number and germline genotype were both measured using the Affymetrix Genome-Wide Human SNP 6.0 array.', {'entities': [(64, 74, 'platform')]}),
 ('There were 500,568 SNPs on the Affymetrix 500K chips and 164,871 on the\nPerlegen custom chip (665,439 SNPs in total).', {'entities': [(72, 80, 'platform')]}),
 (' Of these, 157,048 SNPs failed\nPerlegen’s quality control (20.2% of the Affymetrix 500K and\n33.', {'entities': [(31, 39, 'platform')]})]